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 Abstract 
 
 
 
It is still unknown how tumor exosomes influence malignant cell survival and alter cell-to- 
cell communication to modulate the immune system by, in part, manipulating the activity 
of cytotoxic T lymphocytes. This study focuses on two critical parts regarding cancer 
exosomes. The first part is to tailor existing bionanotechnology methods to account for the 
nanoscale aspects of exosome biology. SEM, TEM, Bioanalyzer and flow cytometry were 
used to characterize exosome morphologies, identify specific protein biomarkers HER1 
and HER2, as well as the quality of RNAs enclosed in exosomes. Competing methods 
related to exosome isolation, production, preservation, stability and analysis were evaluated. 
Based on these studies, we recommend improved experimental methods that aim to ensure 
a consistent framework to identify the roles that exosomes play. With these improved 
methods, the second part is to characterize the immunosuppressive role that melanoma 
exosomes play, especially from the perspective of delivering a payload of mRNAs to 
immune cells. Toward this second aim, melanoma exosomes were purified and cytokine 
receptor IL12Rβ2 and specific mRNA enrichment were identified. Microarray and pathway 
analysis suggested that mRNAs derived from melanoma impact a variety of immune 
signaling pathways. Induction effects of PTPN11 and DNMT3A from the exosomal 
mRNAs were characterized in T lymphocytes. Specifically, we showed that PTPN11 
upregulation impeded CTLL-2 cytotoxic T cell proliferation in response to IL2 stimulation, 
and DNMT3A upregulation hindered IFN-γ production in 2D6 TH1 cells. These findings 
provide insights regarding the specific immunosuppression effects that tumor-infiltrating 
lymphocytes (TILs) may encounter in tumor microenvironment.   Understanding those 
3  
immunosuppression effects is important to engineer anti-tumor immunity for innovative 
and improved treatments against cancer. 
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C H A P T E R  1 I N T R O D U C T I O N 
 
 
 
 
Cancer is the leading cause of death for humans in the modern world. In 2012, 8.2 
million cancer deaths occurred worldwide and is projected to increase to 13.1 million by 
20301. Cancer is a disease involving growth enlargement of malignant cells that can induce 
death when the cancer cells invade to adjacent tissues and disrupt organ function2. 
Treatment for cancer depends on the type and the metastatic stage of the disease when 
detected3. Current treatments include surgery, radiotherapy, chemotherapy, molecularly 
targeted drugs, and immunotherapy. Following a century long incubation period, 
immunotherapy has emerged in the past 5 years as one of the most promising methods to 
achieve a durable response4–8. Cancer immunotherapy promotes the patients’ own immune 
system to attack the tumor5. Since 2011 to 2015, immunotherapy drugs called immune 
checkpoint inhibitors – represented by Yervoy (ipilimumab), Keytruda (pembrolizumab), 
Opdivo (nivolumab) and Arzerra (ofatumumab) – have been approved by FDA and used 
to treat metastatic melanoma and many other types of malignancies 9–11. Since it is capable 
of boosting durable immune response in patients, immune checkpoint modulators have 
achieved remarkable success in improving patient survival. In 2013, a complete cured case 
by ipilimumab for a metastatic melanoma patient was reported (see Figure 1)12. Cancer 
immunotherapies provides proof-of-concept in that harnessing the patient’s immune system 
can be an effective weapon against cancer13. Despite the remarkable effect in some 
patients, the main challenge for broader clinical benefit of these therapies is the low 
response rate, prompting extensive investigations on the disease mechanisms and potential 
improvements in a purpose of enhancing the durable response in immunotherapies14–16. 
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Figure 1. This case report 
showed one patient with 
metastatic melanoma on 
his right arms displayed 
total resolution of the skin 
metastasis by ipilimumab. 
(a and b) Before treatment, 
(c and d) Similar images 
that were taken after 
treatment with 
ipilumimab.12 
 
 
 
 
 
 
While only 2% of all skin cancers, melanoma accounts for the majority deaths of skin 
cancers, with approximately 200,000 cases diagnosed worldwide and 48,000 deaths 
annually17. Risk factors for melanoma incidence include extensive or repeated exposure to 
sunlight, individuals with family history of melanoma (5–12% of all reported cases), high 
nevi counts, and dysplastic nevus. Surgical removal of a melanoma at an early stage is 
effective. Once it metastasizes, melanoma is characterized by rapid progression and a low 
response rate to most conventional cancer treatments5,18, with an average survival ranging 
between 8 -18 months prior to immune checkpoint modulators9,13. As melanoma tumors are 
frequently infiltrated with immune cells, melanoma has long been considered an attractive 
target for immunotherapy19. Moreover, a persistent challenge has been to identify how the 
tumor escapes immune surveillance despite the presence of effector lymphocytes inside 
tumors14,15,20,21. 
 
 
Immune system of vertebrates is resourceful, complex and adaptive to various disease 
pathogens including cancer22. The host immunity contains two distinct but interrelated 
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immunological systems: 1) the innate system to protect against evolutionarily defined 
pathogen-associated molecular patterns, and 2) the adaptive system to protect against 
pathogens by reacting with a nearly limitless molecular patterns and to provide the system 
with long term memory against the specific pathogens. Current cancer immunotherapy is 
mostly based on boosting the adaptive immunity against cancer antigens, in that a cyclic 
process can be generated, leading to an accumulation of immune stimulatory factors and 
amplifying T cell responses (Figure 2)23. As a start of such cancer immunity cycle, 
malignant cells constantly release tumor-antigens into the tissue microenvironment. This 
release is caused by malignant cell death within the tumor that occurs due to the absence of 
appropriate blood supply, which deprives the malignant cells of nutrients and efficient 
waste removal. Dendritic cells (DCs) can sample those tumor-antigens, process the 
captured antigens and present the antigens on MHC class I and/or class II molecules to 
prime effector cellss. The activated dendritic cells migrate to lymph nodes where they can 
stimulate effectors such as T cells and natural killing (NK) cells. Those tumor-specific 
effector T cells together with other effector cells can traffic to the tumor site, recognize 
tumor-antigens through T cell receptor (TCR) and release the cytotoxins (i.e. perforins, 
granzymes, and granulysins) to kill malignant cells that express the corresponding tumor 
antigens. The most common effector cells that can destroy cancer cells are CD8+ and 
CD4+ T cells, and NK cells, through separate mechanisms24–31 (see Table 1). When 
immune cells destroy tumors, more antigens are released, thereby, promote the anti-tumor 
immunity cycle to control tumor growth. 
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Figure 2. The Cancer-Immunity Cycle Against Cancer23. Immune response against cancer can 
boost the cytotoxic T cell activity that is specific to cancer antigens. There are 7 major steps in 
this cycle. Each step involves multiple stimulating and inhibitory factors. Step 1 is release of 
cancer antigens from dying cancer cells due to limited nutrition or oxygen at the inner core of a 
tumor. The APCs detect and intake those antigens nearby the tumors (Step 2), get stimulated 
and migrate to the regional lymph nodes, where naive T cells can be activated and TCR-primed 
by APCs to recognize cancer antigens (Step 3). At this step, native T cells differentiate into CD4+ 
and CD8+ effector T cells, with TCRs specific to cancer antigens. In Steps 4 and 5, effector T cells 
leave lymph, circulate and infiltrate inside tumors, looking for specific cancer antigens expressed 
on MHC class I of tumor cells. TCRs can combine to such antigens on MHC class I (Step 6) and 
anchor circulating effector T cells to cancer cells, stimulates T cell degranulation secreting 
cytotoxic agents, i.e. perforins, grazyme-B, that can destruct cancer cells, as illustrated in Step 7. 
Notably, it is a self-stimulated cycle from Step 1 to 7. Abbreviations are as follows: APCs, antigen 
presenting cells; CTLs, cytotoxic T lymphocytes. 
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Table 1. Melanoma and cellular immune response. 
 
 
Immune 
cells 
 
 
Specificity 
 
 
MHC restricted 
 
 
Killing mechanisms 
 
 
 
NK 
 
 
Innate 
immunity, 
not tumor- 
specific. 
 
 
Lyse a variety of cell lines that have no or 
low MHC class I. Melanomas express 
low level of MHC class I will be killed 
by NK cells. 
 
NK receptors primarily recognized 
"stressed" cells, i.e. tumor cells or 
virus infected cells. Other 
unlicenced killing exists yet is well 
understood. 
 
 
 
CD8+ T 
 
Adaptive 
immunity, 
tumor- 
specific. 
 
MHC class I restricted, recognize/check 
their targets first by TCR. Most 
melanoma express MHC class I, not 
MHC class II are to be killed by tomor- 
specific CD8+ T cells. 
Cytotoxic T lymphocytes that 
infiltrate into tumor and kill cancer 
cells expressing the TCR targets on 
surface. Activated  by TCR, could 
kill autologous and allogeneic 
melanoma. 
 
 
 
 
CD4+ T 
 
 
 
Adaptive 
immunity, 
tumor- 
specific. 
MHC class II restricted recognize/check 
their targets first by TCR. Some 
melanomas express MHC class II and are 
able to be processed and present by 
antigen-presenting cells (i.e. DCs), then 
the antigen will be recognized by CD4+ 
T cells, who is the mediator/helper of 
CD8+ T cells. 
 
 
CD4+ T cells mostly are helper 
cells, bridging the antigen 
presenting cells and CD8+ T cells. 
Recent study showed they are 
capable of killing too. 
 
 
 
Current development of immunotherapy approaches amplify the cancer immunity 
cycle in six main ways (AACR 2015): immune checkpoint inhibitors, adoptive cell 
transfer, cancer vaccines, oncolytic virus therapies, tumor-specific monoclonal antibodies 
and cytokines. In particular, immune checkpoint proteins, such as CTLA4 and PD-1, are a 
variety of surface receptors expressed on the lymphocytes and function in inhibiting T cell 
development, proliferation and effector activities. Immune checkpoint inhibitors target 
those immune regulatory receptors or their ligands, promoting an active anti-tumor immune 
response4,32,33. Adoptive cell transfer (ACT) for cancer therapy expands the patient’s 
tumor-infiltrating lymphocytes (TILs), primarily effector T cells, into large numbers (up to 
1011  cells) in vitro using cytokines, selects T cells having high avidity to tumor antigens 
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and infuses them back to the donor for cancer regression7,28,34,35. As an improved 
alternative to the initial ACT based on TILs, T cells isolated from blood (PBMC) can be 
genetically engineered to express T cell receptors (TCRs) or chimeric antigen receptors 
(CARs) that recognize tumor antigens and are then transferred back to patients. ACT/CAR 
T-cell therapy for metastatic melanoma treatment has achieved an impressive 50% 
response rate in clinical tests with durable tumor eradiation, representing a promising 
direction for cancer therapy36–38. From the cancer-immunity cycle in Figure 2, the immune 
checkpoint inhibitors are trying to enhance the step 7, killing of cancer cells, whilst the 
ACT/CART method promotes effector T cell numbers and tumor-antigen recognition to 
enhance steps 3, 6 and 7, and potentially the steps 4 and 5 are also improved due to more T 
cells in the circulation system. In current development of cancer immunotherapy, immune 
checkpoint inhibitors (i.e. anti-CTLA44,39, anti-PD-1/PD-L140,41)  and ACT 7,42,43 (i.e. CAR 
T) represent the main therapeutic approaches that promote durable anti-tumor response by 
 
enhancing CD8+ T cell numbers and activity. As they can influence almost all steps in the 
cancer-immunity cycle (Figure 2), cytokines can be used therapeutically to regulate anti- 
tumor immunity, as illustrated by therapeutic use of IL2, interferon-α (IFN-α) and 
granulocyte-macrophage colony-stimulating factor (GM-CSF)7,33,44,45. IFN-α is being used 
in a variety of cancer treatment45,46 whereas clinical trial with GM-CSF is undergoing 
investigation47,48. High-dose IL2 has been used as adjuvant for melanoma treatment but has 
been replaced of due to poor responses49,50. IL7, IL12, IL15 and IL21 also are promising 
immunotherapies7,51. 
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Therapeutic cancer vaccines promote the cancer-immunity cycle by providing a source 
of tumor antigens and activating dendritic cells to attack hidden cancer cells52,53. Approved 
by FDA in 2010, Provenge (also named sipuleucel-t) is a personalized therapy for prostate 
cancer. It uses a cancer antigen, prostatic acid phosphatase (PAP) to stimulate the patient's 
own DCs in vitro and infuses the DCs back to the patient to mount immune response. 
Provenge has been shown to extend survival for about 4 months in certain metastatic 
prostate cancer53. Besides, vaccines can be used to prevent cancer as some viruses cause 
cancers, such as hepatitis B virus (HBV) and human papillomavirus (HPV)54–56. 
Alternatively, oncolytic viruses can specifically induce tumor cell lysis, thus releasing 
tumor antigens to initiate therapeutic immune response and can be used to treat multiple 
types of cancers57,58. Another class of immunotherapies are monoclonal antibodies (mAbs). 
One example is bispecific T cell engagers (BiTE, i.e. Blinatumomab) that consists of two 
joined mAbs binding CD3 on T cells and CD19 cancer marker, and bridge T cells with 
cancer cells. Blinatumomab induces 41.6% complete remission in patients and received 
FDA approval in 2014 for acute lymphoblastic leukemia (ALL)59–62. The anti-cancer 
mechanism of blinatumomab is that it enhances the trafficking to and tumor-infiltrating by 
effector T cells (see Figure 2, step 4 and 5), thereby, stimulating the cancer-immunity cycle 
for anti-tumor immune response. Those innovative methods for immunotherapy provides 
improvements and alternative choices in the clinic to radiation, surgery and chemotherapy. 
 
 
Despite the promise of immunotherapy, tumor resists anti-cancer immunity through 
potent and local mechanisms of immunosuppression. Indentifying such interplay between 
cancer and immune cells that modulate tumor progression is a key barrier for expanding the 
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durable immune response in cancer immunotherapy32,63,64. Recently, one type of 
extracellular vesicles with nanoscaled sizes, called exosomes, has been reported vigorously 
in almost all mammalian cells as one special mode of mediators that potentially delivery a 
variety of functional molecules65–68. Exosomes have motivated intense research interests 
for their multiplex roles in intercellular communications within the tumor 
microenvironment, such as between cancer cells and the effector T lymphocytes. Exosomes 
originate from multivesicular bodies (MVBs) of endosomes, as illustrated in Figure 369, 
and are released to the extracellular environment when the MVBs fuse with cell membrane. 
In mammalian cells, exosomes are extracellular vesicles that are about 100nm in diameter, 
with a lipid bilayer membrane that encloses protein and nucleotide contents derived from 
the donor cells. Functional molecules contained in exosomes include protein molecules, 
both from the membrane or the cytosol, as well as coding and non-coding RNAs67,70,71. 
Cancer exosomes derived from cancer cells or cancer patients have been widely reported in 
a variety of cancers, i.e. melanomas, colorectal cancer, breast cancer, prostate cancer and 
others67,72–75. Regarding the protein contents, exosomes from various cell types contain 
300-500 molecules of proteins that are enriched in exosomes, as well as proteins that are 
similarly expressed in donor cells69,76. Previous studies have shown that exosomes derived 
from cancer patients can either stimulate or repress the anti-tumor immune response, as 
tumor-antigens, immunosuppressive receptors and onco-proteins have all been identified 
from tumor exosomes77,78. In addition, exosomes contain various coding and non-coding 
RNAs (mRNAs and miRNAs)70,71, plus small RNAs79–81, which adds an extra layer of 
complexity in evaluating the biological functions of cancer exosomes. One of the 
challenges with identifying the roles of exosomes is that exosome samples are commonly 
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Figure 3. Mammalian cells secrete membrane vesicles69.  The constitutive formation of 
exosomes (around 100 nm in diameter) is special in that it originates from the inward budding 
of cell membrane, forming endosomes that conduct a second inward budding on luminal 
membranes. This process generates multivesicular bodies (MVBs) and exosomes are released to 
extracellular microenvironment when MVBs fuse with cell membrane. Microvesicles (100-1000 
nm in diameters) are constitutively formed by outward budding of the cellular membrane. 
Similarly outward budding occurs for virus secretion in transfected cells. Membrane particles, 
exosome-like vesicles and others have been found from specific types of mammalian cells, yet, 
the mechanisms of their formations have not been fully unraveled. 
 
 
contaminated with a number of micro- and nano-scaled vesicles, vesicle-free protein-RNA 
complexes, lipoproteins and soluble factors that are all present at the extracellular 
milieu69,82. Exosomes, as one specific type of nanoscale vesicles have a relatively uniform 
size and morphology under the electron microscopes69,83. Unfortunately, many methods 
used for sample isolation, characterization and preservation have not been tailored for 
exosome biology, resulting in the controversial and inconsistent findings in this rapidly 
developing field79,84. For instance, different RNA isolation and preparation methods vary in 
exosomal RNA yield and distributions85  (see Figure 4). In addition, many "exosomes" 
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images  shown  in  the  literatures  either  lack  appropriate  sampling  or  contain  obvious 
impurities, as shown in Figure 570,86–88, which suggest improper sample handling. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 4. Total RNAs isolated from 
exosomes using seven different 
isolation kits was analyzed by 
Bioanalyzer85. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Previous publications show "exosomes" images lacking proper number of sampling or 
including obvious impurities. (a)70, (b)86, (c)78 and (d)88 are electron microscopy images of exosomes 
derived from different types of mammalian cells, respectively in previous publications. Sample 
number n are less than 6 in (a), (b) and (c). Left panel in (d) shows more vesicles, however, its 
resolution is low for recognizing vesicle features, size distribution or morphological characteristics. 
100 nm scale bar in all panels (a-d). 
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Based on this scientific context, this thesis focuses on two aspects. First, we tailored 
the existing methods for isolating, characterizing and preserving exosomes derived from 
cancer cells as a way to provide standard and efficient methods for broader use. The 
methods reviewed include electron microscopy for morphological characterization, flow 
cytometry for protein biomarker identification, bioanalyzer to analyze nucleotide acids. 
Using these improved methods, we next characterized the role of cancer exosomes in 
suppressing anti-tumor immunity in a number of melanoma cell models. Specifically, we 
focused on mRNAs from B16F0 melanoma, identified novel expression of mRNA 
enrichments in exosomes compared with the parent cells, and investigated the specific 
functions of PTPN11 and DNMT3A in repressing effector lymphocytes. For the first time, 
we show that B16F0 melanoma exosomes contain intact coding mRNAs that are enriched 
for following genes - Ptpn11, Eif4ebp2, Wsb2, Ptp4a3, Kpnb1, Rnd2 and Actb. Collectively, 
the results provide evidence indicating that coding mRNAs from exosomes are functional. 
We also identified IL12RB2 protein receptors on the surface of B16F0 exosomes, which 
suggests that exosomes reinforce a cytokine sink for IL12 within the tumor 
microenvironment. Taking together, this study provides novel insights into exosome- 
associated immunosuppressive mechanisms present at the tumor sites. 
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C H A P T E R  2 : 
 
E X O S O M E S :  I M P R O V E D  M E T H O D S  T O 
C H A R A C T E R I Z E  T H E I R  M O R P H O L O G Y ,  R N A 
C O N T E N T ,  A N D  S U R F A C E  P R O T E I N 
B I O M A R K E R S 
 
 
 
 
2.1. Introduction 
 
 
 
Coordinated action among a diverse collection of individual cell types within a tissue 
requires robust modes for intercellular communication. Cells receive and transmit 
information through a variety of mechanisms, some of which are well- 
characterized while others remain hazy. Conventional study of these mechanisms 
focuses on direct modes of communication that require cell-to-cell contact or 
indirect modes that rely on the release of soluble biochemical cues. These soluble 
cues are relayed through diffusive and convective transport mechanism and signal 
via receptors. An emerging and controversial mode of communication that blends 
aspects from both categories are exosomes1–3. 
 
Exosomes are nanoscale vesicles derived from the luminal membranes of 
multivesicular bodies (MVBs) and are released to the extracellular milieu when 
MVBs fuse with the cell membrane4,5. Exosomes are reported to convey coding 
RNA6, non-coding RNA7,8, oncoproteins9–11, and antigen presentation molecules12, 
or even DNA13 between cells. By carrying a complex payload of  proteins  and 
RNAs, exosomes may manipulate recipient cells and other organs over a long 
distance6,7,10,14–21.  For  instance,  tumor-derived  exosomes  have  been  reported  to 
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prepare distant sites for metastatic colonization10,22,23 or serve as disease 
biomarkers7,31–34. Alternatively, exosomes may play a local role in shaping the 
development and homeostasis of normal tissues35–38 or in oncogenesis; including 
melanoma10,24,25, ovarian24,26, colorectal27, breast8,20,28, and prostate cancer29,30. The 
spatial organization of tissues depends on convective and diffusive transport 
mechanisms to relay intercellular information. Thus,  the  specific  role  that 
exosomes play may depend highly on size, given the inverse relationship between 
diffusivity in extracellular matrices and molecular size39. 
 
However, one of the challenges with identifying the biological role of 
exosomes in transmitting information between cells is that they are one of  a 
number of extracellular nano- and micro-scaled vesicles that are constitutively 
produced by cells and vary in size, molecular composition, and biological 
function1,40. While the extracellular vesicles field has grown significantly in recent 
years, the controversy associated with the exosome literature is fueled by 
inconsistent nomenclature and isolation methods that result in impure 
preparations41,42. Wondering whether existing methods could distort our view of 
exosome biology, we focused on three important aspects related to obtaining and 
assessing the quality of exosome samples. First, we compared electron microscopy 
methods for assessing population-level exosome morphology, as a  way  to 
distinguish between exosomes and other confounding extracellular vesicles based 
on their size distributions. Second, we compared conditions for producing and 
storing exosomes in vitro in relation to the quality of exosome samples. Third, we 
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developed methods to improve the sensitivity of flow cytometry to assay of protein 
expression on exosomes. 
 
2.2. Experimental 
 
 
 
2.2.1. Materials and reagents 
 
B16F0 cells, a murine model of metastatic melanoma, were acquired from 
American Type Culture Collection (ATCC, Manassas, VA). A HER2+  human 
breast cancer cell line, SKBR3, was kindly provided by Dr. Jia Luo (University of 
Kentucky, Lexington, KY). Dulbecco's Modification of Eagle's Medium (DMEM) 
was from Cellgro (Manassas, VA). Improved Modified Eagle Medium Zn2+ 
option (IMEM, no phenol red) was from  Invitrogen  (Grand  Island,  NY). 
Dulbecco's Phosphate-Buffered Saline (DPBS, 0.1 µm sterile filtered) and heat 
inactivated fetal bovine serum (FBS) was from Hyclone, Inc (Logan, Utah). 
 
TEM (transmission electron microscopy) copper grids (200 mesh and coated 
by formvar carbon film), glutaraldehyde solution, paraformaldehyde (16% 
paraformaldehyde aqueous solution) and 4% uranyl acetate solution were from 
Electron Microscopy Sciences (Hatfield, PA). DNA-free™ DNA removal kit, 
mirVana™ miRNA isolation kit, and SuperScript III First-Strand Synthesis 
System were from Invitrogen. RNA 6000 pico kit, reagents and ladders for Agilent 
2100 Bioanalyzer was from Agilent Technologies (Santa Clara, CA). DEPC water 
was made by mixing distilled water with 0.1% v/v diethylpyrocarbonate for at least 
2 hours at 37 °C and then the water was autoclaved for 30 min. 
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Allophycocyanin (APC) conjugated mouse  anti-human  Her1/ErbB1 
monoclonal antibody (SC-120), phycoerythrin (PE) conjugated mouse anti-human 
HER2/Neu/ErbB2 mAb (SC-23864) and PE conjugated mouse isotype control 
mAbs (SC-2866) were purchased from Santa Cruz Biotechnology (Dallas, TN). 
Human IgG and mouse IgG were from Jackson ImmunoResearch  Laboratories 
(West Grove, PA). APC or PE conjugated mouse anti human/mouse IL-12 receptor 
beta 2 (IL12RB2) mAbs (FAB1959) was from R&D systems (Minneapolis, MN). 
Quantum Simply Cellular microspheres conjugated to anti-mouse IgG were 
purchased from Bangs Laboratories (Fishers, IN). Polystyrene beads  with 
respective diameters 2.19, 0.84 and 0.054 µm and labeled with Nile red were from 
Spherotech, Inc. (Lake Forest, IL). PBSAz for cells was prepared by mixing 2% 
FBS and 0.02% sodium azide in DPBS. PBSAz for exosomes was prepared by 
mixing 0.5% BSA and filtered twice using sterile 0.22 µm filters to exclude 
nanoparticles. Vybrant® DiI lipophilic tracer (DiI, Cat#: V22888) was from 
Invitrogen (Grand Island, NY). 
 
2.2.2. Tissue culture 
 
B16F0 was maintained in DMEM supplemented with 10% FBS and 
penicillin/streptomycin at 37°C, 5% CO2, passaged at 1:5 every 2 days or until 
100% confluence of cells as described previously43. SKBR3 cell culture was 
maintained in 37°C, 5% CO2, correspondingly in supplemented medium as 
described previously20,44. Briefly, SKBR3 was maintained in IMEM supplemented 
with 10% FBS and penicillin/streptomycin that was replaced of every 2 days, and 
passaged at 1:3 every 4-6 days when cells reached 80% confluence. To detach 
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adherent cells, B16F0 or SKBR3, trypsin-EDTA was applied for 7-10 min at 37°C, 
5% CO2  after one wash  by DPBS. After  trypsin treatment, FBS was  added  to 
neutralize and resuspend cells. Cells were washed once in medium before further 
culture or any treatment. 
 
2.2.3. Exosome preparation and isolation 
 
Exosomes were isolated as described previously45. In brief, cell lines were 
cultured until 70% confluence, washed once by DPBS, and incubated with fresh 
serum-free medium for 30min at 37°C and 5% CO2. After 30 minutes, the medium 
was replaced either by serum-free medium (SFM)  or  exosome-free  serum 
containing medium (EFM) and returned to the incubator for the indicated exosome 
production period. The cell-conditioned media were collected at different  time 
points and exosomes were isolated by differential centrifugation as follows: 300 
g for 10 minutes to remove cells, 2,600 g for 10 minutes to remove residual 
 
cells and debris, 10,000 g for 60 minutes to remove microvesicles, and 100,000 
g for 2 hours to collect nano-scaled vesicles in pellets. The resulting pellet was 
resuspended, washed once in DMEM, and re-pelleted at 100,000 g for 2 hours. 
Differential centrifugation was conducted using a Beckman Coulter X-14R 
centrifuge and a Beckman Coulter XL90 ultracentrifuge with proper rotors, open- 
top (Cat#: 355631) or capped (Cat#: 355618, Cat#: 355655) thickwall 
polycarbonate tubes (Beckman Coulter). Once isolated, nano-scaled vesicles were 
resuspended in DPBS and kept on ice. 
 
2.2.4. Exosome cryopreservation 
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Exosomes were preserved in two different ways: directly frozen at -80°C and 
cryopreserved in liquid nitrogen (-196°C) as is typically done with mammalian 
cells. The cryopreservation protocol involved mixing isolated exosomes with equal 
volume of medium containing    2  DMSO (10% or 20%), aliquoting 1ml into 
each cryopreservation tube, wrapping tubes in heat isolated materials and storing 
in a - 80°C freezer overnight (about 16 hr). Samples were then put in liquid 
nitrogen for preservation. To remove from cryopreservation, exosomes were 
thawed on ice for 30min according to45, or 1-2 min at 37°C according to 
recovering cell  lines, washed once in 20ml PBS, and ultracentrifuged to pellet. The 
supernatant was discarded and exosome pellet was resuspended in 200µL-1mL 
PBS for SEM inspection. 
 
2.2.5. Induction of apoptotic and necrotic cell death in B16F0 cells 
 
Extracellular vesicles constitutively produced by cells were compared to 
vesicles released during cell death. To induce apoptosis, B16F0 cells were cultured 
in serum-free medium containing  10µM  7-ethyl-10-hydroxycamptothecin 
(Cayman Chemical Company, USA) for 24 hours, as reported previously46. After 
treatment, B16F0 cells were 70-80% confluence, with visible detached and dead 
cells in the culture. Extracellular vesicles (i.e., apoptotic vesicles) were 
subsequently collected from the B16F0 cell conditioned medium. To induce 
necrotic cell death, B16F0 cells exposed to high shear conditions  by  vigorous 
vortex and extracellular vesicles (i.e., necrotic bodies) were subsequently collected 
from conditioned media.    Apoptotic vesicles and necrotic bodies were isolated by 
differential  (ultra)-centrifugation  that  was  identical  with  the  exosome  isolation. 
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Biological experiments were performed independently at least three times. Each 
biological sample was diluted 4-6 fold, fixed and mounted on substrates,  and 
imaged by electron microscopy (EM). At least 3 EM images were acquired for 
each sample. 
 
2.2.6. Scanning electron microscopy (SEM) 
 
Pellets containing extracellular vesicles isolated from healthy cells (i.e., 
exosomes) and from apoptotic and necrotic cells were vortexed and resuspended 
in 0.2-1 ml DPBS. Exosomes and nano-scaled apoptotic  vesicles  or  necrotic 
bodies (micro-scaled parts of apoptotic vesicles or necrotic bodies were removed 
prior to ultracentrifugation) were fixed in a 2% EMS-quality paraformaldehyde 
aqueous solution. The samples were then diluted in distilled (dl) water in serial 
dilutions, added in 1-5 µl vesicle mixtures to cleaned silicon chips, which were 
sonicated in acetone, ethanol and distilled water for 5 min in each solvent, flushed 
by water and blown dry, and immobilized after drying vesicles under a ventilation 
hood. Samples on silicon chips were mounted on a SEM stage by carbon paste. To 
make surface conductive, a coating of 2-5 nm gold-palladium alloy was applied by 
sputtering (SPI-Module Sputtering, Argon as gas for plasma) before imaging by 
scanning electron microscopy Hitachi S-4700 or a JEOL JSM-7600F SEM. SEM 
was performed under low beam energies (5.0-10.0 kV). For  best  vesicle 
morphology under SEM, fresh isolated exosomes were fixed and immobilized on 
silicon right after isolation, and imaged within 7 days. Analysis of exosome sizes 
were  done  using  the  SEM  images  via  ImageJ  and  the  density  distribution  of 
exosome diameters were obtained using R/Bioconductor. 
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2.2.7. Transmission electron microscopy (TEM) 
 
Exosomes were produced by incubating cells in serum free medium for 24 hrs. 
Freshly isolated exosomes from mouse melanoma B16F0 cells were resuspended 
in cold DPBS containing 2% para-formaldehyde. Exosome samples were prepared 
for TEM inspection as described previously45. Briefly, exosomes were mounted on 
copper grids, fixed by 1% glutaraldehyde in cold DPBS for 5 min to stabilize the 
immunoreaction, washed in sterile distilled water, contrasted by uranyl-oxalate 
solution at pH 7 for 5 min, and embedded by methyl cellulose-UA for 10 min on 
ice. Excess cellulose was removed and samples were dried for permanent 
preservation. A JEOL 1010 TEM was used to image exosome samples at a voltage 
of 80kV. 
 
2.2.8. Statistical analysis 
 
Extracellular vesicle sizes are reported in terms of diameters (mean ± standard 
deviation). Comparisons among multiple groups were performed with one-way or 
two-way ANOVA methods depending on the factors using SPSS statistics 20. The 
statistical difference in means between two different groups were compared using 
a two-sided Student’s t-test with unequal variance, where a P value < 0.05 was 
considered as significant. 
 
2.2.9. Exosomal RNA (esRNA) 
 
To characterize exosomal RNA, total RNA were isolated from cells, fresh 
exosome or frozen exosome pellets using a mirVana™ miRNA isolation kit (Life 
Technologies) according to the manufacturer’s protocol. DNase digestion was then 
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 performed to remove possible contaminating DNA  (DNA-free™  DNA removal kit). After isolation, cellular RNA nd exosomal RNA was stored at -80⁰C until 
 
characterized using a NanoDrop 2000 Spectrophotometer (Thermo Scientific) and 
on-chip-electrophoresis via Agilent 2100 Bioanalyzer and RNA 6000  pico  kit. 
Strict RNA handling guidelines were followed during assays with RNA. 
 
B16F0 cellular RNA and esRNA were reversely transcribed with  the 
SuperScript III system. B16F0 genomic DNA was isolated using Genomic DNA 
Purification Kit (Thermo Scientific). The cDNAs, together with  genomic  DNA 
about 10% of RNA input, were used to amplify the full-length coding sequences 
(ORFs) or part of introns of the indicated genes  by  semi-quantitative  PCR,  in 
which the amplified DNA products were monitored from certain cycles after the 
desired fragments showed up, and compared  before  the  amplification  was 
saturated. The primer sequences are listed in Table 1. 
 
Table 1. Primers used for semi-quantitative PCR. 
 
Genes (mouse) Amplicon Primers Sequences 
Eif4ebp2 ORF Forward ATGTCCGCGTCGGCCGGTG 
  Reverse TCAGATGTCCATCTCAAACTGAG 
 Intron # 1 Forward GTAGAGGCGCTGTCAGGTTT 
  Reverse CCCGACTAGTGTGTGCTGTT 
Wsb2 ORF Forward ATGGAGGCCGGAGAGGAG 
  Reverse CTAGAAAGTCCTGTATGTGAGG 
 Intron # 1 Forward GTAGGTCCCGACACCCTAGT 
  Reverse CCATCCCTAGCATCTCTGCG 
Rnd2 ORF Forward ATGGAGGGGCAGAGTGGC 
  Reverse TCACATGAGGTTACAGCTCTTG 
 Intron # 1 Forward GCATCAGAGGATCCGGAAGG 
  Reverse GGTCCAGCTCAGTCCCTAGA 
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2.2.10. Western blot analysis 
 
Western blot analysis was used to confirm that exosome samples contained 
proteins commonly associated with exosomes. For immunoblotting, rabbit  anti- 
CD9, CD63, CD81, Hsp70 antibodies were from System Biosciences (Mountain 
View, CA), mouse anti- β-actin and β-tubulin were from Santa Cruz 
Biotechnology, Inc. (Dallas, Texas). B16F0 cells and exosomes were lysed with 
ice-cold radio immunoprecipitation assay buffer (RIPA, 150 mM sodium chloride, 
1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) 
supplemented with protease and phosphatase inhibitors. The protein concentration 
was determined using Pierce BCA Protein Assay Kit  (Life  Technologies),  and 
20µg of each sample was resolved for SDS-polyacrylamide gel electrophoresis. 
Proteins were transferred to Bio Trace PVDF membrane (PALL Life Sciences, 
Pensacola, FL) and detected using Pierce ECL Western Blotting Substrate (Life 
Technologies). 
 
2.2.11. Flow cytometry 
 
Isolated exosomes and cells were resuspended in PBSAz, blocked by 1/100 
(v/v) human IgG in PBSAz for 15 min on ice, and stained using appropriate 
antibodies for 30 min on ice in the dark. After staining, exosomes were washed 
with PBSAz and ultracentrifuged by    150,000 g for 1 hour at 4⁰C. The 
exosome 
pellet   was   resuspended   in   PBSAz   and   a   final   volumetric   percent   of   2% 
 
paraformaldehyde was added to preserve samples at 4°C for flow cytometry for up 
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to 2 weeks. 
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Flow cytometry was performed as described previously using a FACSAria or a 
LSRFortessa flow cytometer and analysis software (BD Biosciences). Briefly, 
cellular copy numbers of HER1 and HER2 were estimated using Quantum Simply 
Cellular calibration beads. The fluorescent intensity for each parameter was 
reported as a pulse area using 18-bit  resolution.  Unstained  cells  and  exosomes 
were used as negative flow cytometry controls and singly stained cells and 
exosomes were used to establish fluorescent compensation parameters. When 
exosomes were analyzed by flow cytometry, events were detected when the side 
scatter area was above a threshold that was established using running buffer. 
Following acquiring at least 20,000 events, flow cytometry data was exported as 
FCS3.0 files and analyzed using R/Bioconductor, as described previously48. 
 
2.3. Results and discussion 
 
 
 
2.3.1. SEM provides a quick alternative to TEM for characterizing the morphology 
and distribution of exosomes. 
 
Exosomes are one of a number of different micro- and nano-scaled vesicles 
released by cells that can be distinguished based upon their morphology and size 
distribution. Electron microscopy (EM) is necessary to characterize their 
morphology since particles smaller than 300 nm are invisible in optical methods49. 
Though transmission EM (TEM) is considered a standard tool for characterizing 
the morphology of exosomes, scanning EM (SEM) is an alternative approach that 
has recently emerged50. In general, TEM and SEM both require ultracentrifugation 
to isolate exosomes, include sample processing steps prior to EM, and use electron 
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beams to detect the nanostructures with high resolution. However, the number of 
sample processing steps are different between the two methods. The first aim of 
this study was to compare these two EM methods for  characterizing the 
morphology of exosomes, as to distinguish them from other extracellular vesicles. 
To illustrate these methods, exosomes were isolated by differential centrifugation 
from two cell lines – B16F0, a mouse melanoma cell line, and SKBR3, a human 
breast cancer cell line – and were processed immediately for electron microscopy 
to image fresh vesicles Under SEM, extracellular vesicles isolated from normal 
cells exhibited a round morphology and uniform, unimodal distribution in size that 
was consistent with exosomes (Figure 1A, subpanels i and ii for B16F0 exosomes, 
subpanels iii and iv  for SKBR3 exosomes). In contrast to exosomes, apoptotic 
vesicles and necrotic bodies derived from B16F0 cells displayed irregular shapes 
and a heterogeneous size distribution, as observed by SEM (Figure 1B, apoptotic 
vesicles, APV (left); necrotic bodies, NCB (right) ). TEM was also used to 
characterize the morphology of B16F0 exosomes, where a central depression was 
observed, which is a characteristic for exosomes under TEM (Figure 1C). The size 
distributions of the different extracellular vesicles and exosomes imaged using 
different EM methods were compared (Figure 1D and Table 2). Using both EM 
methods, we also noted that dispersing samples containing extracellular vesicles as 
a monolayer on the silicon substrate improved the image quality significantly. In 
summary, we found that B16F0 exosome diameters were not significantly different 
between the two EM methods (P value > 0.05). This is interesting as it suggests 
that the two EM methods provide the same measurement of exosome sizes 
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Figure 1 Different extracellular vesicles exhibited different morphologies and size 
distributions, as imaged by SEM and TEM. (A) Exosomes (EXO) isolated from B16F0 mouse 
melanoma cells (subpanels i and ii) and SKBR3 human breast cancer cells (subpanels iii and 
iv) were imaged by SEM. (B) Extracellular vesicles isolated from apoptotic B16F0 cells that 
were treated with  7-ethyl-10-hydroxycamptothecin (left panel, apoptotic vesicles APV). 
Necrotic bodies (NCB) were isolated from B16F0 cells following exposure to high shear 
conditions (right panel). APV and NCB were imaged by SEM. (C) Exosomes from B16F0  
cells were imaged by TEM (scale bar = 200 nm). (D) The size distributions of EXO, APV, and 
NCB observed by electron microscopy. (left panel) B16F0 EXO observed by SEM (black  
solid line; n = 113) or TEM (gray shaded; n = 14), and SKBR3 EXO under SEM (dotted line; n 
= 237). (right panel) B16F0 vesicles observed by SEM, including EXO (black solid line; same 
data as in left panel), APV (gray shaded) and NCB (dotted line). All images were 
representative of a least three biological replicates. See Table 2 for comparisons and 
statistics. 
 
 
 
Table 2 Size comparisons and statistics of exosomes, apoptotic vesicles and necrotic 
bodies that were isolated and observed by electron microscopy. 
 
 
Vesicle Isolated 
 
EM 
 
Diameter ± 
SD 
 
N 
 
**P values for statistical 
significance 
B16F0 Exosomes 
(EXO) 
 
SEM 
 
162 ± 23 nm 
 
113 N.S., B16F0 EXO imaged by SEM vs. 
TEM; 
P<0.001, B16F0 EXO vs. APV or NCB 
in SEM. 
 
B16F0 Exosomes 
 
TEM 
 
158 ± 19 nm 
 
14 
 
SKBR3 Exosomes 
 
SEM 
 
183 ± 34 nm 
 
237 
P<0.001,   SKBR3   EXO   vs.   B16F0 
EXO, in SEM 
B16F0 Apoptotic 
vesicles (APV) 
 
SEM 
131 ± 148 nm 
* 
 
602 
P<0.001, B16F0 APV vs. B16F0 EXO 
or NCB, in SEM. 
B16F0 Necrotic bodies 
(NCB) 
 
SEM 
 
70 ± 38 nm * 
 
222 
P<0.001, B16F0 NCB vs. B16F0 EXO 
or APV, in SEM. 
 
* Size distributions did not exhibit unimodal distributions. Mean diameters were calculated from projected 
areas of all particles that exhibit round or irregular shapes. **P values were accessed using one-way ANOVA 
or Student’s t-test. SD is standard deviation. N is sample number of observed vesicles in EM. N.S. is not 
significant. 
 
 
regardless of the morphological differences observed under the two EMs, such as 
the “cup-shape” observed by TEM. In contrast, APC and NCB from B16F0 cells 
did not exhibit unimodal distributions as observed with exosomes. In addition, the 
size distributions of APC and NCB were significantly different from exosomes (P 
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< 0.001). B16F0 exosomes were also slightly smaller than the SKBR3 exosomes 
(162 nm vs. 183 nm, respectively; P < 0.001). 
 
Similar diameters have been observed by EM imaging for  cancer exosomes 
from B16F10 (closely related to B16F0) mouse melanoma cells25, from human 
plasma of melanoma patients10 and from SKBR3 human breast  cancer  cells20. 
While the average sizes of the extracellular vesicles that we have observed are 
slightly higher than previous reports of exosomes50,51, their uniform  size 
distribution rules out apoptotic and necrotic bodies, which were heterogeneously 
distributed and irregularly shaped (Figure 1 A-D).  Discrepancies  could  be 
attributed to the cellular source of exosomes or to differences in sample isolation 
and SEM preparation. For instance, it has been reported that exosomes derived 
from the human HEK cell line 293T shrunk in size by 50% within 8 days, from 
116 to 63 nm in diameter, when stored in PBS at 4 ºC 50. 
 
Morphological differences were apparent when identical samples of exosomes 
were imaged with these two different EM techniques, where TEM images show a 
characteristic central depression in the exosomes and SEM images show exosomes 
as round spheroids. We observed that the SEM images for exosomes derived from 
two different cell lines were consistently spheroidal, as similarly observed with 
exosomes from human saliva51. While early work suggests that exosomes exhibit a 
characteristic central depression, this trait is an artifact attributed to TEM sample 
preparation, such as embedding the exosomes in polymeric cellulose, rather a 
physiological  features  of  exosomes41,52.  In  comparing  these  two  EM  methods, 
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TEM sample preparation includes steps for gradient dehydration, contrasting 
staining by heavy metals and embedding the sample in polymeric cellulose, which 
are omitted in preparing SEM samples. We also note that all the images shown in 
Figure 1 were obtained using fresh samples. Differences in methods for storing 
extracellular vesicles can also introduce artifacts, as we will discuss a later section. 
 
Collectively, the imaging results suggested that SEM and TEM provide similar 
information regarding the size distribution but a slightly different morphological 
view of exosomes and other extracellular vesicles. Currently, EM methods are the 
standard practice for direct imaging the size and morphology of exosomes. 
However, there are some trade-offs to consider when comparing  the  TEM and 
SEM. For instance, preparing TEM samples requires more steps compared with 
SEM sample preparation. The SEM images of exosomes, apoptotic vesicles, 
necrotic bodies, shown in Figure 1, exhibited intact membrane structures and the 
morphologies were distinctly different for each type of nanoscale vesicles. This 
finding suggested that SEM is a valid alternative to TEM for direct imaging of 
extracellular vesicles, with advantages based on the improved sample process 
methods. 
 
The morphology and size of extracellular vesicles, including exosomes, are 
critical in defining their physiological roles, distribution, and concentrations in 
organs53,54,55. Observing nanoscale vesicles under physiological conditions in situ 
using an electron beam is a challenge, as a high vacuum, 10-5 to 10-8 Torr, and 
anhydrous  atmosphere  are  required.  However,  reducing  the  number  of  sample 
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fixing and processing steps streamlined the pursuit of the native morphologies of 
exosomes.  To  illustrate  this  point,  we  also  found  that  B16F0  and  SKBR3 
exosomes  frequently  appeared  as  clusters  of  multiple  exosomes  (2-10  particles, 
approximately) with membranes connected tightly or even merged in SEM images, 
suggesting that the natural morphology of B16F0 and SKBR3 exosomes are as 
multi-exosome clusters instead of isolated exosomes (Figure 1A). In contrast, the 
clustering phenomena were not observed under SEM with other nanoscale vesicles, 
such  as  apoptotic  vesicles  or  necrotic  bodies  (Figure  1B).  This  suggests  that 
clustering is not due to sample processing, such as forming clusters due to the 
capillary effects of water drops during evaporation. This observation may be due to 
minimal processing of the samples afforded by SEM imaging. However, clustering 
of native exosomes has implications for other indirect methods for characterizing 
exosomes,  like  dynamic  light  scattering  or  nanoparticle  tracking  analysis,  that 
assume that the particles are isolated vesicles49,56,57. The results also imply that 
filtering samples through a 0.2 micron filter prior to ultracentrifugation, which is 
common practice, would actually enrich for vesicles associated with cell death. In 
addition, TEM imaging using nanoparticle-conjugated antibodies can be used to 
identify  whether  exosomes  contain  membrane  proteins45,  The  use  of  SEM  for 
immuno-gold   labeling   studies   of   cell   samples   remains   in   development58,59. 
Alternative  methods  also  exist  for  quantifying  membrane  protein  expression  on 
exosomes, as we discuss in a later section. Next, we used SEM to evaluate the 
effects  of  other  process  parameters  associated  with  producing,  isolating,  and 
storing exosomes from cell-conditioned media. 
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2.3.2. A survey of exosome production methods and their impact on exosomal RNA 
quality 
 
Fetal bovine serum (FBS) is a common supplement to eukaryotic cell culture 
media; yet, animal serum can contain exosomes that can contaminate cell-derived 
exosome populations. In this study, we evaluated the impact of two media options 
for limiting FBS-derived exosome contamination on in vitro production of cell- 
derived exosomes. The two media options were serum-free medium (SFM) and 
medium supplemented with serum that had been cleared of exosomes by 
ultracentrifugation, that is exosome-free serum-containing medium (EFM). Media 
were conditioned with B16F0 cells for different lengths of time. In both SFM and 
EFM, B16F0-derived exosomes could be isolated under all conditions. The size 
distributions of exosomes isolated from the B16F0-conditioned SFM and EFM at 
each time point were determined from SEM images (Figure 2A), The size 
distributions of B16F0 exosomes purified from SFM or EFM, at the indicated 
incubation times (12-48 hrs) with the B16F0 parental cells, were assessed for 
statistical differences by two-way and one-way ANOVA analysis. These size 
distributions were found to be not significantly different with respect to the 
incubation medium types and with respect to the incubation times. A shift  in 
particle size distribution towards smaller sizes would suggest that the culture 
conditions decreased cell viability, as observed by the tail in the distribution of 
vesicles obtained after conditioning for 48 hours in serum free media. 
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Figure 2 Exosome quality was evaluated in terms 
of vesicle morphology and exosomal RNA as a 
function of production condtions. (A) B16F0 
exosomes were produced using serum free 
medium (SFM) or exosome-free serum medium 
(EFM) for 12, 24, 36 and 48 hours and 
characterized using SEM (n = 51, 73, 76 and 53 
for SFM exosomes, from 12-48 hrs,; n = 68, 213, 
91, 210 for EFM exosomes, from 12-48 hrs, 
respectively). In the box plots, the top and 
bottom of the boxes indicate the 75% and 25% of 
the distribution in sizes, black bands on the boxes 
indicate the median sizes, top and bottom bars 
indicated the maximum and minimum of the 
sizes. The exosome sizes were assessed using 
two-way and one-way ANOVA and found to be 
not significantly different. Multiple SEM pictures 
and biological samples, n ≥ 3, were used to 
determine the exosome sizes. (B) Electrophoresis 
spectrums of exosomal and cellular RNA derived 
from B16F0 cells using Agilent Bioanalyzer. The 
positions of 18S and 28S peaks on the RNA 
spectrums were indicated in diagrams by arrows 
and labels. esRNAis for exosomal RNAs. 
Representative figures of RNA analyses were 
shown, n > 3. 
 
 
In addition, exosomal RNA (esRNA) was also characterized by on-chip- 
electrophoresis using an Agilent Bioanalyzer (Figure 2B), which can  quickly 
assess the quality of RNAs purified from exosomes. As RNA become degraded, 
longer RNAs become fragmented such that the distribution shifts entirely towards 
the low end (< 200 nt in length). Following a single wash of exosome pellets in 
DMEM alone, exosomal RNAs were isolated from exosome pellets obtained from 
B16F0-conditioned serum free medium after 24 (top panel) and 48 (middle panel) 
hours incubation with cells. For comparison, RNA was isolated from whole B16F0 
cell lysates and analyzed similarly (bottom panel). The results are representative of 
at least three replicates. 
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Overall, we found that fresh exosomes contained high quality RNA. Analysis 
of esRNA did not contain the characteristic peaks associated with ribosomal RNA, 
as observed previously7 (see reduced 18S and 28S peaks labeled in Figure 2B). 
The presence of the 28S peak, in particular, may indicate the presence of 
contaminating cell debris. The distribution in esRNA was primarily uniform but 
was limited to below 1800 nucleotides in length. This distribution in RNAs is not 
surprising, as we used the mirVana miRNA isolation kit that uses a column to 
enrich small RNAs. Finally, longer production times were also associated with a 
shift in distribution in esRNA to smaller length RNA, as illustrated by the 
difference between the 24 hr and 48 hr esRNA samples. While this shift in esRNA 
 
 
A 
 
WCL EXO 
B 
 
 
 
Hsp70 
CD63 
CD81 
 
  cDNA   
Cellular   Exosomal 
 
 
Amplicons 
Eif4ebp2 ORF 
(Full length, 363bp) 
 
Eif4ebp2 Intron #1 
(Partial, 83bp) 
 
 
Wsb2 ORF 
(Full length, 1215bp) 
 
    CD9 
    β-actin 
 
β-tubulin 
 
Wsb2 Intron #1 
(Partial, 115bp) 
 
 
Rnd2 ORF 
(Full length, 684bp) 
 
Rnd2 Intron #1 
(Partial, 196bp) 
 
Figure 3 Biochemical characterization of exosomes from B16F0 cells. (A). Immunoblotting 
analysis of common exosome markers, where 20µg of total protein was loaded in each lane 
(WCL, whole cell lysate; Exo, exosome lysate). (B). Amplification of the full-length protein ORFs 
and partial introns by semi-quantitative RT-PCR suggested that a group of functional mRNAs 
are enriched in exosomes. 100ng of RNAs were reverse-transcribed into cDNA and subject to 
PCR amplification as indicated. 10ng of genomic DNA (10%) was also used as quality control 
(left lane). 
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was slight, degradation of RNA shifts the distribution towards lengths below 200 
nucleotides7. Collectively, we observed no difference in exosome quality between 
SFM and EFM and that prolonged production conditions slightly degraded the 
quality of esRNA. 
 
We also biochemically characterized samples to support the claim that these 
samples contain exosomes with high quality RNA. Specifically, Western blot 
analysis of samples indicated the presence of common markers of exosomes, such 
as Hsp70, CD63, and CD9 (Figure 3A), while CD81, β-actin and β-tubulin were 
 
 
absent. Whole cell lysates were used as  a positive control; yet, the absence of 
appropriate loading controls renders the analysis qualitative. In  our  hands,  we 
found that exosomal RNA contained mRNA transcripts of protein open reading 
frames with no contaminating genomic DNA (Figure 3B). This is in contrast to 
reports that suggest that exosomes contain mRNA fragments63, which may be an 
artifact of storage conditions that we will discuss next. 
 
2.3.3. Preservation and stability of exosomes and RNAs at low temperatures 
 
 
 
To understand the role that exosomes play in intercellular communication, 
cellular assays need to be performed that identify how exosomes influence cellular 
function in a dose-dependent fashion and independent from direct cell-to-cell 
interaction. To demonstrate these influences in a reproducible manner, exosomes 
should be stored under conditions that preserve their biological activity once 
isolated   from   cell-conditioned   media.   Conventional   methods   suggest   that 
exosomes  can  be  preserved  by  freezing  at   -80ºC12.  Alternatively,  dimethyl 
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sulfoxide (DMSO) is used as a cryoprotectant when cells are preserved in liquid 
nitrogen. To determine the impact of these two different freezing options on 
exosome quality, we froze B16F0 and SKBR3 exosomes at -80ºC in serum free 
medium and in serum free medium supplemented with 10% DMSO. Following 
thawing on ice, the exosomes were imaged using SEM (see Figure 4A for B16F0 
frozen exosomes, and Figure 5B for SKBR3 frozen exosomes). Images show that 
cryopreservation in serum free medium alone resulted in smaller (10-100 nm in 
diameter) and more heterogeneous shapes to the frozen exosome samples, in 
comparison with the fresh exosomes (Figure 4B). Specifically, SEM images 
indicated that the diameters of the frozen exosomes were 44 ± 15 nm for B16F0 (n 
= 508) and 34 ± 8 nm for SKBR3 (n = 354). These size distributions were 
significantly different from each other as well as from fresh exosomes (see Figure 
1D and Table 2), which was assessed using one-way ANOVA (P value < 0.001). 
Our analyses suggested that direct freezing affects the stability of the exosome 
membranes and degrades the samples. 
 
In contrast, the morphology of exosomes cryopreserved using DMSO was 
similar to SEM images of fresh exosomes (compare panels C and D in Figure 5, 
with Figure 1A). Though sizes and shapes of a certain percentage of exosomes 
were preserved, DMSO was unable to preserve the morphology of all vesicles in 
the sample. Collectively, the results suggested that DMSO  could be used as a 
cryoprotectant to help maintain the morphology of these vesicles for long-term 
39  
 
 
 
Figure 4 Freezing of exosomes decreased their size and degraded exosomal RNA. (A) SEM 
pictures of B16F0 exosomes subjected to a freeze-and-thaw cycle. (B) The size distributions of 
frozen exosomes processed from B16F0 (blue solid line, diameter 44 ± 15 nm, n = 508) and  
SKBR3 (blue dotted line, diameter 34 ± 8 nm, n = 354) cells, in comparison with the fresh 
exosomes from B16F0 (black solid line, diameter 162 ±  23 nm, n = 113) and SKBR3 (black dotted 
line, diameter 183 ± 34 nm, n = 237) cells. The data for fresh exosomes are also shown in Figure 
1D-i and Table 2. The sizes of the four exosome samples are statically different as assessed by 
one-way ANOVA (P value < 0.001). (C and D) Bioanalyzer results for exosomal RNAs isolated from 
exosomes frozen at -80 ºC to -196 ºC in media alone (C) or with 5-10% DMSO as cryoprotectant 
(D). Exosomes were stored frozen for 9 days (C top panel), 2 months (C middle panel), or 2 years 
(C bottom panel and D). The shift in nucleotide size towards small, degraded RNA is indicated by 
black dashed arrows. A hump around 1000 nt was observed in samples frozen for 2 years in 10% 
DMSO (solid arrow in D bottom panel). Representative figures were shown, n > 3 as for SEM of 
the biological samples; n>3 for RNA analysis and isolation. 
 
 
 
storage.   However,  cryostorage   also  negatively  impacted   the  morphology  of 
 
exosomes, as the exosomes became smaller and more heterogeneous in size. This 
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Figure 5 SEM images of frozen exosomes from mouse melanoma cells B16F0 (A, C and D) and 
human breast cancer cells SKBR3 (B). (Panels A and B) Exosomes were stored at -80°C in 
serum free medium for 1-2 weeks, thawed on ice, fixed by paraformaldehyde and examined 
by SEM. (C and D) Exosomes from B16F0 were frozen at -80 C in serum free medium with 5- 
10% DMSO as a cryoprotectant and thawed on ice, or at 37°C quickly as thawing cells. 
 
 
implies that cryostorage makes it more difficult to assess the quality of the sample 
by distinguishing between exosomes and vesicles derived from dead cells. Without 
confirming the quality of the exosome sample, the biological implications of 
downstream assays using these samples would be unclear. 
 
Besides morphology, preserving the biological activity of RNAs in exosomes 
is also crucial for studying exosome biology in a reproducible manner. Using an 
Agilent Bioanalyzer, we characterized exosomal RNAs that were isolated from 
exosomes frozen for various periods of time (Figure 4C) or cryopreserved with 
DMSO (Figure 4D). In Figure 4C, RNAs isolated from exosomes frozen for 9 days 
and 2 months, still contained a variety of RNA molecules spanning from 18S to 
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smaller length nucleotides, featuring the characteristics of  RNAs  isolated  from 
fresh exosomes (compare with Figure 2B, top and  middle).  However,  freezing 
those exosomes for 2 years resulted loss of the 18S and obvious shifting in RNA 
distributions towards smaller nucleotides (Figure 4C, bottom), as indicated by a 
dashed black arrow. Collectively, the results suggest that exosomal RNA was 
preserved in frozen exosomes for a couple of months,  but  was  degraded  with 
longer times. This degraded RNA signature can also be observed in previous 
exosome studies (for example6, 64,65). To check whether DMSO could also preseve 
exosomal RNAs, exosomal RNAs purified from frozen exosomes  stored  for  2 
years with 5-10 % DMSO were analyzed by Bioanalyzer (see Figure 4D). In these 
samples, RNA appeared to be degraded, as shown by the enrichment of smaller 
RNAs (see the dashed black arrows in Figure 4D). There was also an odd peak at 
around 1000 nucleotides of the RNA spectrum (see the solid arrow in Figure 4D 
bottom), which is possibly an artifact attributed to DMSO. The results here 
indicated that DMSO was unable to preserve exosomal RNAs (Figure 4D), though 
the size and morphology of vesicles could be protected by DMSO during low 
temperature storage and the thawing process (C and D in Figure 5). Collectively, 
the results suggest that sample quality should be established using fresh exosomes 
and that prolonged storage in the freezer degrades biological activity. 
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2.3.4. Flow cytometry as an unbiased tool to characterize exosomal membrane 
protein expression 
 
A number of different techniques have been proposed to isolate exosomes from 
biological fluids. To bypass the time-consuming ultra-centrifugation step, 
exosomes have been isolated using “exosome markers”, that are proteins contained 
in the external lipid bilayer. Exosomes can be purified using these exosome 
markers and capture beads. Exosomes bound to these capture beads can then be 
analyzed using a conventional flow cytometer60. Collectively, flow cytometric 
analysis of exosomes is high-throughput with the capacity for quantitative protein 
characterization60. Recently, a high-end dedicated flow cytometer with higher 
sensitivity forward scatter detection and fluorescent amplification has been 
developed to separate stained exosomes from background contaminants61. 
However, it is unclear whether these isolation and detection methods are biased. A 
potential source of bias may be exosome heterogeneity, as translating cellular the 
protein copy numbers on exosomes may be in the single digits. Since many 
institutions do not have dedicated instruments for studying extracellular vesicles, 
we modified a conventional flow cytometer to use SSC instead of FSC to detect 
transmembrane protein copy number to nanometer-sized exosomes suggests that 
flow cytometric events and characterized the heterogeneity of transmembrane 
protein abundance among an exosome population and assessed the sensitivity of 
this approach. 
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SKBR3 cells and exosomes isolated from conditioned media  were  stained 
using fluorophore conjugated antibodies against two members of the epidermal 
growth factor family of receptors: HER1 and HER2 (Figure 6). As the SKBR3 cell 
line is considered a cell model for HER2+ breast cancer, the cells  exhibited 
positive staining for both HER1 and HER2  (Figure  6A).  Using  antibody 
calibration beads (see Figure 7), the median cellular copy numbers of HER1 and H 
ER2 on SKBR3 cells were estimated to be 1.41×105 copies of HER1 and 1.43×106 
copies of HER2 per cell. As expected, SKBR3 cells contained ten times higher 
copy numbers of HER2 than HER1 on the surface. Next, we assayed HER1 and 
HER2 abundance in SKBR3 exosomes by flow cytometry (see Figure 6B). The 
SKBR3 exosomes were clearly positive for HER2 staining, while HER1 staining 
was not significantly different from unstained exosomes. Cells and exosomes 
stained using isotype controls also displayed no difference from unstained cells or 
exosomes (data not shown here). 
 
 
 
Figure 6 The abundance of the membrane proteins, HER1 and HER2, were quantified on SKBR3 
exosomes and the parental cells by flow cytometry. SKBR3 cells (A) and SKBR3 exosomes (B) 
were assayed for HER2 (left panels) and HER1 (right panels) abundance using fluorophore- 
conjugated antibodies and flow cytometry. Unstained exosomes and SKBR3 cells were used as 
negative controls (gray shaded). (C) Flow cytometric analysis of SKBR3 exosomes double-stained 
with APC-conjugated HER1 mAbs and DiI, a lipophilic fluorescent dye.  (left panel: (i)) The density 
distribution of fluorescence associated with HER1 staining in DiI-positive events (black line) was 
bimodal and was deconvoluted into two normal distributions associated with single (red curve) 
and DiI-clustered exosomes (blue curve). The upper limit for APC-MFI of single exosomes is 
indicated by the gray vertical line. (right panel (ii)) A scatterplot of MFIs associated with HER1 
staining versus DiI staining of SKBR3 exosome samples. The threshold to detect DiI-MFI is 
indicated by the red dashed horizontal line. The vertical green line indicates a data-driven 
threshold where 95 percent of unstained exosomes (gray shaded in left panel) exhibited a lower 
MFI associated with APC fluorescence. 
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Figure 7 Calibration of HER1 and HER2 expression on SKBR3 cells to equivalent copy numbers 
per cell by flow cytometry using quantum calibration beads. Copy number expression was 
obtained using five quantum simply cellular microsphere populations, one blank and four 
labeled with increasing amounts of anti-mouse IgG antibody, that exhibit a defined antibody 
binding capacity. Probability density functions for the five microsphere populations stained 
using Alexa 647-conjugated anti-HER1 mAb (Panel A) and uing PE-conjugated mouse anti- 
HER2 mAb (Panel C). Plots of the median MFI for the four antibodystained microspheres 
versus the corresponding antibody binding capacity, expressed in molecules per bead (HER1 - 
panel B, HER2 - panel D). 
 
 
Conventionally, cellular events are recognized in flow cytometry by their 
forward and side scatter properties. The forward scatter area is proportional to the 
cross-sectional area of an object as it flows by the laser and side scatter is related 
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to the complexity of the object to scatter light. To identify whether we could 
distinguish exosomes from background debris, we used flow cytometry to quantify 
the forward scatter properties of fluorescent nanoparticles that bracketed the 
expected size range of exosomes (Figure 8). In comparison to the fluorescent 
nanoparticles, we found that exosomes exhibited forward scatter areas between the 
forward scatter area of 54 nm PE beads and 840 nm PE beads and similar to 
background debris. These results suggest that non-exosome events may confound 
the interpretation of HER1 staining of SKBR3 exosomes. In addition, flow 
cytometry using fluorophore-conjugated antibodies may not  be  sufficiently 
sensitive to detect the low copy number of HER1 on exosomes. Using the cellular 
copy numbers of HER1 on SKBR3 cells, the average HER1 copy number on each 
exosome is 47 and ranges from 30-70, assuming that a SKBR3 cell can be 
modelled as a sphere with a diameter of 10 µm52 and that SKBR3 exosomes have 
an average diameter of 183 ± 34 nm (Figure 1B). 
 
Similar to the detection of fluorescent nanoparticles, fluorescence can be used 
to distinguish a flow cytometric event associated with true particle different from 
background debris. Therefore, we used a lipophilic dialkylcarbocyanine dye, DiI, 
to label exosomes for flow cytometric detection. To determine whether DiI 
improved exosome detection by the flow cytometry, we stained B16F0 exosomes 
using a 2x2 factorial experimental design with APC-conjugated monoclonal 
antibody against IL12RB2 and DiI as the two factors (see Figure 9). We found that 
the no stain and the mAb-stained only groups were very similar in their forward 
scatter area. Interestingly, we also found that DiI-stained samples increased the 
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Figure 8 Forward scatter area is proportional to particle size. Forward scatter area versus the 
fluorescence levels of 3 different sized beads that are fluorescently labeled (A) and the 
standard curve of particle sizes versus their respective forward scatter area (B). The three sets 
of beads have nominal diameters of 2.19, 0.84 and 0.054 µm, respectively. 
 
 
 
 
 
 
Figure 9 Flow 
cytometric analysis of 
B16F0 exosomes 
stained using APC 
conjugated IL12Rβ2 
mAb and the lipophilic 
dye DiI. 
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forward scatter areas above the background, suggesting that DiI may be clustering 
the exosomes. To demonstrate how the lipophilic tracer DiI can be used to enhance 
detection of proteins on exosomes using flow cytometry, we revised the flow 
cytometry assay to detect HER1 proteins on SKBR3 exosomes. As single 
exosomes, SKBR3 exosomes were negative for HER1 staining (see Figure 6B) in 
our result, to increase the HER1 signal, we stained SKBR3 exosomes using an 
APC-conjugated HER1 mAb and then clustered them into larger particles using 
DiI (Figure 6C). The DiI positive events exhibited a bimodal distribution, where 
single exosomes exhibited a distribution similar to  the unstained control  (mean 
MFI = 11.4 a.u. versus mean MFI = 0 a.u. for unstained) and exosome clusters 
exhibited a broad distribution (mean MFI = 778 a.u.). On a flow cytometric event 
basis, the single exosomes seem to be a large fraction of the population. However 
considering that events exhibiting a MFI greater than 100 a.u. are comprised of 
multiple exosomes, the number of single exosomes was estimated to be less than 
1% of the total exosome population. 
 
Collectively, the flow cytometry results suggested two points. First, the 
sensitivity of the flow cytometry assay limited our ability to assess exosome 
biomarkers to those proteins that exhibited high copy numbers. As an alternative to 
using antibodies that are directly conjugated to fluorophores, a primary antibody 
directed against the protein of interest plus a fluorophore-conjugated secondary 
antibody that binds to multiple epitopes on the primary antibody may improve the 
ability  to  detect  lower  abundant  proteins,  as  used  in62.  While  a  polyclonal 
secondary  antibody  may  improve  the  detection  signal,  the  mean  fluorescent 
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Figure 10 Exosomes were clustered 
using the lipophilic tracer DiI. Exosome 
clusters had more HER1 copies and 
bigger particle sizes, which enhanced 
HER1 detection by conventional flow 
cytometry using anti HER1-APC mAbs. 
(A) A schematic diagram illustrating that 
DiI was used to cluster nanoscaled 
exosomes into microscaled clusters. (B) 
A representative SEM image of DiI 
clustered exosomes,  where “Exo” 
indicates the clusters of exosomes and 
black arrows indicates the edges of 
microscaled clusters induced by DiI. 
 
 
 
 
 
 
 
 
 
 
intensity cannot be used in this context to quantify exosomal copy number, as 
described here. Second, a lipophilic dialkylcarbocyanine tracer (i.e. DiI, in  this 
work) can be used to enhance the detection of low copy number proteins through 
unbiased clustering of exosomes and creating a lipophilic phase that favour the 
clustering of exosomes. This observation is schematically  illustrated  in  (Figure 
10A) and also supported by SEM imaging of exosomes stained by DiI (Figure 
10B). Moreover, the addition of the lipophilic tracer enabled discriminating 
exosome-related flow cytometric events from background debris. This unbiased 
clustering increased the detection of the fluorescent signal associated with 
antibody binding. Collectively, these results illustrate how conventional flow 
cytometric   analysis   can   be   improved   to   leverage   the   high-throughput   and 
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quantitative   potential   of   the   method   to   characterize   protein   expression   on 
exosomes with minimal potential bias. 
 
2.4. Conclusions 
 
 
 
In summary, we found that subtle differences in producing and storing 
exosomes can distort experimental observations of the purity of exosome samples, 
the size of exosomes, and the quality of exosomal RNA. In comparing two 
methods for direct imaging using electron microscopy, scanning electron 
microscope (SEM) provided a less time-consuming alternative to transmission 
electron microscope (TEM) to image the native morphology of exosomes and to 
assess sample purity. Using SEM, we were able to assess the impact of  two 
different cell culture media on exosome production and of storage conditions on 
exosome quality. Within the first 24-36 hours, using serum-free media during 
exosome production did not appreciably alter exosome quality. The isolated 
exosomes also contained intact RNA transcripts. If the isolated exosomes need to 
be stored for a prolonged period, DMSO can be used to cryopreserve the 
morphology of exosomes but the sample quality is best characterized using fresh 
samples. In terms of biological activity, exosomal RNAs were preserved by 
freezing for short periods of time but became degraded  with  prolonged 
cryostorage, which may alter function. We also show that flow cytometry can be 
used to detect the presence of membrane-bound proteins on exosomes without 
specific bias toward any potential subpopulation in exosomes. Protein epitopes at 
high copy numbers could be readily detected while the lipophilic tracer, DiI, was 
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used to cluster exosomes and enhance the detection of lower copy number 
proteins. The flow cytometry results also demonstrate that exosomes isolated from 
SKBR3 cells, a model of human HER2+ breast cancer, contain HER1 and HER2, 
two members of the epidermal growth factor family of receptors. Exosomes are 
approximately 100-times smaller in diameter than the mammalian cells and, 
therefore, contain less HER1 or HER2 copies in  comparison  with  the  parental 
cells. In addition, we found that the relative densities of HER1 and HER2 on the 
membrane surfaces were similar in SKBR3 exosomes as they were in the parental 
SKBR3 cells. In closing, we hope that, by identifying  key  process  parameters, 
these improved methods will help to ensure a consistent framework in identifying 
the role that exosomes play in regulating cell-to-cell communication. 
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C H A P T E R  3 : 
 
M E L A N O M A  B 1 6 F 0  E X O S O M E S  D E L I V E R  A 
U N I Q U E  B U T  C O M P L E X  B I O L O G I C A L 
P A Y L O A D  T O  S U P P R E S S  T  L Y M P H O C Y T E 
F U N C T I O N 
 
 
 
 
3.1. Introduction 
 
 
 
Recent clinical successes using immune checkpoint modulators (i.e. anti- 
CTLA-4, anti-PD-1/anti-PD-L-1) and adoptive cell therapy using engineered 
CD8+ T cells (chimeric antigen receptor T cells, called CAR T cells) are exciting 
developments in using immunotherapies for the treatment of cancer 1–3. While the 
clinical response in a subset of cancer patients is quite durable, expanding  the 
clinical benefit to the broader patient population remains a  challenge4,5.  These 
recent studies suggest that the clinical regression of a solid tumor is correlated with 
immune contexture within the tumor microenvironment and the local infiltration of 
active cytotoxic T cells. Specifically, proliferating CD8+ T cells are present 
throughout tumors in patients who respond well to anti-PD-1 therapy 6. In contrast, 
tumors from patients that do not respond to therapy exhibit one of three patterns of 
CD8+ T cells: little to no infiltration of CD8+ T cells, CD8+ T cells present but 
non-functional, and  an increased density of  CD8+ T  cell around the  tumor 6,7. 
These clinical data complement a broad body of literature suggesting that potent 
immunosuppressive mechanisms are present  within the tumor microenvironment 
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and  play  major  roles  in  suppressing  the  anti-cancer  activities  of  cytotoxic  T 
lymphocytes8. 
 
Organizing host immunity against a malignancy involves engaging a variety of 
immune cell types through a complex network of intercellular interactions.  As 
tumors develop, they alter this network of interactions to construct a tissue niche 
favoring malignant cell survival that includes malignant cells, supportive stromal 
cells, alterations in the extracellular matrix, changes in metabolic substrates, and 
an immunological context associated with regulatory T cells, myeloid-derived 
suppressor cells, and inflammatory cytokines that suppressed anti-tumor immunity 
9,10. Interestingly, an immunosuppressive environment within a tumor can be 
established relatively quickly. For instance, the ability of an anti-CTLA-4 therapy 
to control tumor growth using a variant of the B16 model of metastatic melanoma 
depended on time such that administration of an anti-CTLA-4 therapy up to 4 days 
after tumor implantation was able to eliminate tumors while waiting 12 days after 
implantation abrogated the therapeutic effect 11. Similar to the selection and editing 
of tumor-associated antigens12, the results suggest that profile of proteins secreted 
by malignant cells may also reflect the selective pressure associated with 
oncogenesis. To develop this hypothesis, we used a proteomics workflow to 
identify proteins secreted into media conditioned by B16F0 cells, that is the B16F0 
secretome, and found that the majority of secreted proteins were associated with 
exosomes13. 
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Exosomes are nano-scaled membrane vesicles derived from the endocytic 
compartments of mammalian cells and are released constitutively by both normal 
and malignant cells14. Emerging as an important mode of intercellular 
communications, exosomes can potentially transfer a variety of  functional 
molecules including proteins, lipids, and coding and non-coding RNAs between 
cells. Transmembrane receptors and ligands that regulate and suppress the activity 
of immune cells have also been identified on tumor exosomes (9, 10). Previous 
studies have reported that melanoma exosomes deliver onco-protein MET to 
BMDCs that can stimulate pre-metastatic transformation in distant organs 15,16. 
Focused studies on particular miRNA Exosome production and release are thought 
to be enhanced by a p53-mediated stress response 17 and can be inhibited by 
depleting Rab27 family proteins that are involved in intracellular trafficking and 
release of exosomes18. While microarrays have been used to characterize in a 
systematic way the distribution of exosomal RNAs relative to the parental cells19–23 
, a re-analysis of these data suggests that exosomal RNAs are primarily fragmented 
 
24. In contrast, more focused studies suggest that exosomes can deliver biologically 
active miRNAs and mRNAs that can be translated in recipient cells 19,21,23. As we 
have recently found that common methods for exosome storage degrade exosome 
morphology and the quality of exosomal RNA 25, the objective of this study was to 
characterize exosomes freshly isolated from three different  cell  models  of 
melanoma with a particular emphasis on exosomal mRNA and their  potential 
impact  on  T  cell  function.    Specifically,  we  focused  on  the  B16F0,  a  non- 
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immunogenic cell model of malignant melanoma; Cloudman S91, a cell model of 
immunogenic melanoma; and Melan-A, an immortalized melanocyte cell line. 
 
3.2. Materials and Methods 
 
 
 
3.2.1. Antibodies and reagents. 
 
Cytokines,  drugs,  kits,  and  pharmacological  inhibitors  were  obtained  from 
commercial sources and used according to the suppliers’ recommendations unless 
otherwise indicated. Western blot Abs: IL12RB2 pAbs (Santa Cruz Biotechnology; 
clone M-20) and GAPDH mAbs (Cell Signaling Technology; clone 14C10); LI- 
COR  IR  secondary  Abs  (LI-COR  Biosciences).  Fluorophore-conjugated  mAbs 
were used in flow cytometry: PE-PTPN11 mAb (Santa Cruz Biotechnology; clone 
B-1), PE-IFN-γ mAb (BD Pharmingen; clone XMG1.2), DyLight 488-DDK mAb 
(OriGene  Technologies;  clone  4C5),  PE-IL12RB2  mAb  (R&D  Systems;  clone 
305719). Isotype control mAbs were rat and mouse mAbs conjugated with PE, 
APC (BD Biosciences). Blocking reagent was mouse IgG (Jackson Laboratory) in 
PBSAz for cells (DPBS mixed with 2% FBS and 0.02% sodium azide). Phosflow 
Lyse/Fix   buffer   and   Perm   Buffer   III   (used   in   PTPN11   mAbs   staining), 
Cytofix/Cytoperm Fixation/Permeabilization kit (used for IFN-γ mAbs and DDK- 
protein-tag mAbs staining) were from BD Biosciences. CellTrace Violet (CTV) 
and Live/Dead Yellow staining were purchased from Invitrogen. PBSAz buffer for 
exosomes is DPBS mixed with 0.05% BSA and 0.02% sodium azide, which was 
double-filtered  through  0.02  µm  filters.  CD8a+  T  Cell  Isolation  Kit  II,  anti- 
CD3ε/anti-CD28   beads   for   T   cell   activation   (anti-CD3/CD28   beads),   and 
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fluorophore-conjugated Abs used in CD8 T cell staining including  APC-CD3ε 
mAb, VioBlue-CD8α mAb, FITC-CD44 mAb, and PE-CD62 mAb were from 
Miltenyi Biotec Inc. 
 
3.2.2. Mice and primary T cell isolation. 
 
Eight- to 12-week-old transgenic B6.Cg-Thy1a/Cy  Tg(TcraTcrb)8Rest/J 
female mice were obtained from Jackson Laboratory. Mice were housed in 
sterilized microisolator cages in the university vivarium, and facility sentinel 
animals were regularly screened for specific pathogen agents. All studies were 
performed in accordance with all federal and institutional guidelines for animal use 
and were approved by the West Virginia University IACUC. From mouse spleen, 
primary CD8+ T cells were isolated from mouse splenocytes by automated 
magnetic cell sorting using methods described previously 26 and by using  the 
CD8α+ T Cell Isolation Kit II according to the manufacturer’s instructions. 
Enrichment for naive  CD8+  T cells (CD8+, CD3+, CD44-, and CD62L+) was 
confirmed by flow cytometry using corresponding Abs conjugated with 
fluorophores. 
 
3.2.3. Cell line culture and stimulation. 
 
The mouse melanoma cell lines, B16F0 and Cloudman S91 (clone M-3), and a 
cytotoxic T lymphocyte cell line, CTLL-2, were acquired from American Type 
Culture Collection (ATCC). An immortalized mouse melanocyte cell line, Melan- 
A, was provided by V. Hearing (National Cancer Institute, Bethesda, MD, USA) 
27. The TH1 cell model, 2D6, was provided by M. Grusby (Harvard University, 
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Cambridge, MA) and cultured as described previously 28. B16F0 and Cloudman 
S91 cells were maintained 29 in DMEM (Cellgro/Corning) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS, Hyclone) and penicillin/streptomycin 
(Gibco). Melan-A cell line was maintained in DMEM supplemented with 10% non-
heat-inactivated FBS, 20 mM hydrogen chloride, 10 mM HEPES (Gibco), 100 U/ 
ml penicillin and 100 µg/ml streptomycin (penicillin/streptomycin), 200 nM 12- o-
tetradecanoyl phorbol 13-acetate (TPA, Sigma) and 200 µM phenylthiourea (PTU, 
Sigma). CTLL-2 cell line was maintained in RPMI 1640 medium supplemented with 
10% T-STIM without con A containing IL-2 (BD Biosciences), 10% FBS,  
penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 
1.5 g/l sodium bicarbonate, 10 mM HEPES, 4ppm β-mercaptoethanol (β-ME; 2 µl 
in 500 ml medium). Primary CD8+ T cells were cultured in RPMI 1640 
supplemented with 10% FBS, penicillin/streptomycin, 2 mM L-glutamine, 1 mM 
sodium pyruvate, 10 mM HEPES, 4 ppm β-ME, 70 U/ml IL-2, 90 pM rmIL-12 
(eBiosciences), 5 µg/ml anti IL-4 mAb (eBiosciences), with or without the co- 
stimulation from anti-CD3/CD28 beads (1:1 cell:bead ratio). All cells were 
cultured at 37°C in 5% CO2. 
 
3.2.4. Exosome isolation, scanning electron microscopy (SEM) imaging and Western 
blot analysis. 
 
Fresh extracellular vesicles were isolated using a differential centrifugation 
protocol from serum-free media that have been conditioned by the B16F0, 
Cloudman S91 and Melan-a cell lines, respectively, for the indicated time periods 
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and imaged using SEM, as described previously 13. Exosome sizes were quantified 
from the SEM images using ImageJ and summarized as distributions using kernel 
density estimation in R 2.15.2. All numbers are reported as mean ± standard 
deviation, unless otherwise noted. The abundance of proteins contained in B16F0 
exosomes were compared against whole cell lysates of B16F0 by Western blot 
targeting IL12RB2 and GAPDH, using methods as described previously30. Whole 
cell lysates from 2D6 cells were used as a positive control. In summary, protein 
samples were denatured by Laemmli sample buffer plus βME, loaded onto a 8% 
Tris polyacrylamide gel with a 4% stacking gel for SDS-PAGE, and then 
transferred to a PVDF membrane (PALL Life Sciences) for blotting. Following 
blocking by SEA blocking buffer (Pierce), membranes were probed with mixed 
primary Abs of goat anti-mouse IL12RB2 pAb (1:300, clone M-20, Santa Cruz 
Biotechnology) and rabbit anti-mouse GAPDH mAbs (1:2000, clone 14C10, Cell 
Signaling Technology) in 5% dry milk in PBS-T (PBS plus 0.1% Tween-200 and 
0.04% sodium nitride), then incubated in secondary Abs conjugated with 
fluorophores (1: 20,000 IRDye800CW donkey anti-goat IgG Abs, 1: 60,000 
IRDye680LT donkey anti-rabbit IgG Abs, LI-COR Biosciences) in PBS-T 
supplemented with 5% dry milk and 0.01% SDS, rinsed in PBS-T , and imaged 
using the Odyssey Infrared Imaging System (LI-COR). 
 
3.2.5. Microarray analysis. 
Total RNA isolated from B16F0 exosomes and cells by RNeasy Plus kit 
(Qiagen) was quantified using Nanodrop and analyzed by on-chip-electrophoresis 
using  the  Agilent  Bioanalyzer.  RNA  sample  (100  ng)  with  an  RNA  integrity 
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number value greater than 7 was processed by the Ambion WT Expression Kit 
according to the manufacturer's instructions. Each reaction yielded between 6 to 9 
micrograms of cDNA, whereby 5.5 μg of cDNA was fragmented and labeled with 
biotin by the GeneChip WT Terminal Labeling Kit (Affymetrix). The efficiency of 
fragmentation reaction was checked via Agilent Bioanalyzer. The entire reaction of 
fragmented and biotin-labeled cDNA (50 µl) with  added  hybridization  controls 
was hybridized to the mouse GeneChip 1.0 ST Exon Arrays (Affymetrix) at 45°C 
for 17  hours in  GeneChip Hybridization  Oven  640 (Affymetrix). Mouse 
GeneChip 1.0 ST Exon Arrays were stained using FS 450_0001 protocol in 
Affymetrix GeneChip Fluidics Station 450. Phycoerythrin labeling was detected 
within the Affymetrix GeneChip Scanner 3000 7G plus using 532 nm light and 
detected by a photomultiplier tube. Expression Console software (Affymetrix) was 
used to check quality controls of hybridized chips. All chips that passed quality 
controls were RMA normalized using Expression Console software. Gene 
expression was estimated based on the average expression of all core probesets for 
a gene. The probability of a gene being expressed above background by random 
chance was estimated using the negative control probesets and a Welch's t-test, 
where the degrees of freedom were calculated using the Welch-Satterthwaite 
equation. A p-value of less than 0.05 was used for estimating the distribution of 
mRNA expression between cells and exosomes while a p-value of less than 1e-9 
was used for qRT-PCR validation and pathway enrichment analysis. 
Quantitative reverse-transcription PCR (q-RT-PCR) was used to validate the 
cDNA microarray results. RNA samples were purified using an RNeasy mini kit 
64  
 
(Qiagen) and reversely transcribed with Superscript III First-Strand (Invitrogen). 
Quantitative PCR was carried out on an ABI PRISM 7900HT Sequence Detection 
System (Applied Biosystems) using Perfecta SYBR Green SuperMix, ROX 
(Quanta Biosciences). Proprietary primer mixtures were purchased from Qiagen 
for   the   corresponding   genes:   Kpnb1   (Cat.   #   QT00153419),   Rnf14   (Cat. 
#QT00157241), Rnd2 (Cat. #QT00314216), Ptp4a3 (Cat. #QT00138243), Eif2c2 
 
(Cat. #QT01757833), Hipk2 (Cat. #QT00197890), Eif4ebp2 (Cat. #QT00144606), 
 
Dnmt3a (Cat. #QT00106519), Wsb2 (Cat. #QT01747739). The delta/delta CT 
method using the Sequence Detector Software version 2.2 (Applied Biosystems) 
was for data analysis. In addition, the semi-quantitative PCR was used to amplify 
the full-length coding sequences (ORFs) of the indicated genes from same cDNAs, 
in which the amplified DNA products were monitored from certain cycles after the 
desired fragments showed up, and compared  before  the  amplification  was 
saturated. The primer sequences are listed as follows: Ptpn11 forward 
ATGACATCGCGGAGATGGTTTC, reverse 
TCATCTGAAACTCCTCTGCTGCTG; Kpnb1 forward 
ATGGAGCTCATAACCATCCTCG,   reverse 
TCAAGCCTGGTTCTTCAGTTTCC; Ptp4a3 forward 
ATGGCCCGCATGAACCGGC,     reverse     CTACATGACGCAGCATCTGGTC; 
Eif4ebp2 forward ATGTCCGCGTCGGCCGGTG, reverse 
TCAGATGTCCATCTCAAACTGAG; Rnd2 forward 
ATGGAGGGGCAGAGTGGC,  reverse  TCACATGAGGTTACAGCTCTTG;  and 
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Wsb2 forward ATGGAGGCCGGAGAGGAG, reverse 
CTAGAAAGTCCTGTATGTGAGG. 
 
3.2.6. Cell stimulation with exosomes. 
 
Prior to exposure to exosomes, 2D6 T cells (6 × 104 cells/well) were cultured 
in 96-well u-bottomed culture plates for 12 h in the absence of IL-12p70. 
Following pre-conditioning, 2D6 T cells were stimulated with complete media 
containing the indicated concentrations of fresh exosomes that had been isolated 
aseptically from B16F0, Cloudman S91 and Melan-A cells, and resuspended in 
PBS. Cells were cultured with exosomes for 30 min at 37°C in 5% CO2 and then 
prepared for flow cytometric analysis, as described in28. Briefly, cells were fixed 
using Phosflow Lyse/Fix buffer, permeabilized using Perm Buffer  III,  blocked 
using mouse IgG, stained using PE-PTPN11 mAb, and suspended in PBSaz for 
flow cytometry analysis. 
 
Prior to exposure to exosomes, primary CD8+ T cells were stained by 
CellTrace Violet (CTV). Following CTV staining, primary CD8+ T cells (6 × 104 
cells/well) were cultured in 96-well u-bottomed culture plates for 24 hours at 37°C 
in 5% CO2 in complete media containing anti-CD3/CD28 beads at a 1:1 ratio with 
cells and the indicated concentrations of fresh exosomes that were isolated 
aseptically from B16F0, Cloudman S91, and Melan-A cells. Primary CD8+ T cells 
cultured in complete media that contained only blank beads at a 1:1 ratio was used 
as a negative control. At the indicated time points, cells were stained using 
Live/Dead Yellow, fixed using  Phosflow Lyse/Fix buffer, blocked using mouse 
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IgG, stained with PE-IL12RB2 mAb, resuspended in PBSaz and analyzed by flow 
cytometry. All experiments were performed in triplicate. 
 
3.2.7. PTPN11 transfection and assay of CTLL-2 T cell proliferation. 
 
CTLL-2 T cells were transiently transfected with two different Ptpn11 
expression plasmids with CMV promoters (Cat.# MC219480  for isoform variant 
1, Cat.# MC219394 for isoform variant 2, OriGene Technologies), and a GFP 
expression plasmid with a CMV promoter (pmaxGFP Vector from Lonza) using a 
Nucleofector electroporation 2b device, program L-029 and solution L (Lonza). 
CTLL-2 cells electroporated in the presence of plasmid TE buffer was used as a 
negative control. Following transfection, cells were cultured in calcium-free 
medium containing 10% FBS at 37ºC for 10 minutes and then cultured in complete 
medium containing 50 ng/ml TPA (PMA; Sigma) to induce gene expression for 40 
hours. Following this pre-conditioning period, CTLL-2 cells  were  labeled  with 
CTV to record cell proliferation, transferred in triplicate to 96-well-plate at  a 
density of 1 × 105 cells/ml and stimulated with 2000 U/ml IL-2 for the indicated 
time points, up to 72 hrs. After IL-2 stimulation, cells stained with  Live/Dead 
Yellow, fixed, permeabilized, blocked, stained using PE-conjugated PTPN11 
mAbs and subjected to flow cytometric analysis. At least two biological replicates 
of transfection where performed. For each batch of transfected cells, experiments 
were performed in triplicates. 
 
3.2.8. DNMT3A transfection and assay of IFN-γ production in 2D6 T cells. 
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DNMT3A expression was induced using two different CMV-driven 
expression plasmids that contained isoforms of Dnmt3a with a C-terminal myc- 
DKK tag (MR211146 Dnmt3a variant 1, MR226152 Dnmt3a variant 2; OriGene 
Technologies) 2D6 T cells were transfected and recovered in complete medium for 
48 hrs containing TPA as it was performed on CTLL-2 T cells, except using 
Nucleofector program T-030 for electroporation. Following this pre-conditioning 
period, 2D6 T cells were cultured without IL-12p70 for 12 hrs, transferred in 
triplicate to 96-well-plate, u-bottom, at a density of 6 × 105 cells/ml, stimulated for 
5 hours with 1 µg/ml calcium ionophore (Sigma), 25 ng/ml TPA and GolgiStop 
monensin (protein transport inhibitor; BD Biosciences) in complete medium 
without IL-12p70. Incubating 2D6 cells in medium containing monensin, without 
calcium ionophore or TPA was used as a negative control. After the stimulation, 
cells were stained by Live/Dead Yellow staining,  fixed,  permeabilized,  stained 
with DyLight488-conjugated anti-DDK mAb and PE-conjugated anti-IFN-γ mAb, 
and analyzed by flow cytometry. 
 
3.2.9. Flow cytometry. 
 
Immunostaining of  surface  proteins  on  exosomes was performed  using 
methods described28. In brief, freshly isolated exosomes were resuspended in 
PBSAz buffer, blocked using mouse  IgG, stained with PE-conjugated IL12RB2 
mAb, washed in 20 ml PBSAz and spun down at    150,000 g for 1 hour at 
4⁰C. 
Stained exosomes were then resuspended in 0.5-1 ml PBSAz supplemented with 0.04%  paraf rmaldehyde  (Electron  Microscopy  Sciences),  and  stored  at  4⁰C 
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before flow cytometry  analysis.  For all flow cytometric analyses, FACSAria  or 
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LSRFortessa flow cytometers were used (BD Biosciences). The fluorescent 
intensity for each parameter was reported as a pulse area using 18-bit resolution. 
Single-stain controls were used to establish fluorescent compensation parameters. 
Unstained cells were used as negative flow cytometry controls. Flow cytometry 
data was exported as FCS3.0 files and analyzed using R/Bioconductor software31. 
 
3.2.10. Statistics. 
 
The differences in Western blots were compared for statistical significances 
using Student’s t-test. RNA expressions in  Microarray  analysis  were  compared 
with the loading controls using Welsh t-test. Statistically significant differences in 
PE MFI (IFN-γ) distributions were compared using a Pearson’s χ2 test.  P value < 
0.05 was considered as statistically significant. 
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3.3. Results 
 
 
 
3.3.1. Exosomes are secreted by both normal and malignant melanocytes. 
 
 
 
In a previous proteomic study of B16F0 secretome, we identified that the 
majority of secreted proteins were associated with exosomes 13. To validate and 
extend this prior work, we isolated extracellular vesicles from in vitro cell cultures 
of mouse melanoma cells, B16F0 and Cloudman S91, and from immortalized 
melanocytes, Melan-A, using a differential centrifugation protocol. As cells secrete 
exosomes in addition to a number of other extracellular vesicles, we used scanning 
electron microscopy (SEM) to image directly the morphology and size distribution 
of these isolated extracellular particles. The extracellular particles exhibited round 
morphology (see Figure 1) with frequent membrane connections between the 
nanoscaled vesicles. In analyzing the SEM images, we found that the extracellular 
vesicles were uniformly distributed with average diameters of 163 ± 13 nm (n = 
66) for B16F0 exosomes, 160 ± 18 nm (n = 62) for Cloudman S91 exosomes, and 
166 ± 22 nm (n = 123) for Melan-A exosomes. Given that apoptotic vesicles and 
necrotic vesicles exhibit heterogeneous distributions with smaller sized vesicles 
under EM25 and our prior proteomics analysis of the B16F0 secretome, we 
concluded that the isolated extracellular vesicles secreted by all three cell lines 
were exosomes. 
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Figure 1 Mouse melanoma and immortalized melanocytes release exosomes. Extracellular 
vesicles were isolated from media conditioned by B16F0 cells (a), Cloudman S91 (b), and 
Melan-A cells (c) and imaged using SEM (bar indicates 500 nm used for a, b and c). SEM images 
were representative of more than 3 replicates. (d) The diameters of the extracellular vesicles 
from B16F0 (black solid line, N = 66), Cloudman S91 (black dotted line, N =62), and Melan-A 
cells (gray shadowed, N =123) were estimated from the SEM images using ImageJ and 
summarized using a density distribution, where the density distributions were offset vertically 
for clarity. 
 
 
 
3.3.2. B16F0 exosomes express IL-12RB2 on the surface. 
 
 
 
Exosomes have been reported to transport transmembrane receptors between 
cells 32. In29, we observed that the B16F0 cell line overexpressed IL12RB2, which 
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Figure 2. Similar to parental cells, exosomes isolated from B16F0 cells contain IL-12 receptor beta 
2 (IL12RB2), which is localized on the exosome surface. (a) A Western blot analysis identified 
IL12RB2 as being present in B16F0 exosomes, B16F0 cells and 2D6 T cells, as illustrated by a 
representative image (a) and normalized intensity ratios (b) (* P < 0.001, N = 4). GAPDH was a 
loading control and whole cell lysate from 2D6 T cells was used as a positive control for IL12RB2 
expression. (c) The presence of IL12RB2 on the surface of exosomes was detected by flow 
cytometry using IL-12RB2 mAbs-PE. Unstained exosomes were used as a negative control (gray 
shaded). Results were representative of three replicates. 
 
is one component of the Interleukin-12 (IL12) receptor, and that the B16F0 
sequestered IL12. Collectively, the results suggest that the B16F0 cells create a 
cytokine sink for IL12. Here, we wanted to know whether exosomes released by 
the B16F0 cells also contained IL12RB2. In comparing B16F0 exosome lysates 
with whole cell lysates, Western blot analysis revealed a single band with an 
apparent molecular weight of 130 kDa for samples from B16F0 cells as well as 
B16F0 exosomes (see Figure 2a). As a positive control, we also included whole 
cell lysates from 2D6 T cells, which activate STAT4 in response to IL12 
stimulation28. The relative abundance of IL12RB2 appeared to be more in the 
exosomes compared to either the B16F0 or 2D6 T cells (see Figure 2b, p < 0.001), 
where GAPDH was used as a loading control, as it is present in both cells and 
exosomes. As IL12RB2 may be encapsulated within the exosomes rather than 
expressed on the surface, we stained exosomes using a PE-conjugated IL12RB2 
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antibody and analyzed exosomes using flow cytometry, which indicated that 
B16F0 exosomes expressed IL12RB2 on the surface (Figure 2c). Collectively, the 
results suggest that B16F0 cells release exosomes with an average diameter of 163 
nm that contain IL12RB2 on the surface. 
 
3.3.3. Exosomes contain intact mRNAs that exhibit differential enrichment relative to 
the parent cells 
 
As exosomes have been reported to contain coding RNA, we used an exon- 
level cDNA Affymetrix microarray to quantify mRNA transcripts in B16F0 
exosomes and the parental B16F0 cells. First, we used an Agilent Bioanalyzer for 
on-chip-electrophoresis to assess the quality and the distribution in length of RNA 
in samples isolated from B16F0 cells and freshly isolated B16F0 exosomes (Figure 
3a). In contrast to the predominant peaks associated with ribosomal RNAs (5S, 
18S, and 28S) in the samples from B16F0 cells, the exosome samples had RNA 
that was broadly distributed between the 120 and 1800 nucleotides in length and 
were negative for 28S ribosomal RNA. Affymetrix microarrays were then used to 
quantify differential expression of mRNA between B16F0 cells and exosomes. 
Hierarchical clustering was used to illustrate differences among the different 
samples versus among  the probed genes (Figure 3b). Overall the samples were 
similar between replicates of the same RNA source and different between the cell 
and exosome samples. In comparing the ratio of average expression between 
exosome and cell samples, we found that 67% mRNAs probed were more 
prevalent in the cell, 30% of the mRNAs were equally distributed between the cell 
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Figure 3 B16F0 exosomes contain mRNAs that are differentially expressed relative to parental 
cells. (a) The distribution in RNA contained within the parental B16F0 cells (top panel) and B16F0 
exosomes (bottom panel) was quantified using microfluidic electrophoresis (Agilent 2100 
Bioanalyzer). (b) Hierarchical clustering of mRNA detected above background (p < 0.01) from four 
B16F0 exosomes and four B16F0 cell samples using Affymetrix Exon-level cDNA microarrays. (c) 
The overall distribution in exosome versus cellular abundance of mRNAs (gray curve) was 
deconvoluted into three normally distributed populations: mRNAs enriched in cells (red curve – 
67% of total), mRNAs equally distributed between cell and exosomes (black curve – 30% of total), 
and mRNAs enriched in exosomes (blue curve – 3% of total). (d) Using a more stringent gene call 
(PGene< 1e-9), a Venn diagram summarizes the number of mRNA genes differentially expressed 
between cell and exosome samples. 
 
and exosome, and 3% of the mRNAs had a higher abundance in the exosomes 
(Figure 3c, P <0.01 vs. the negative control probesets). Using a Bonferroni 
correction for multiple hypothesis testing, a Venn diagram summarized the 
distribution in the gene expression that were significantly above background. In 
particular,  we  focused  on  145  mRNAs  for  genes  that  were  more  abundant  in 
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Figure 4. Relative mRNA abundance between B16F0 exosomes and cells were consistent 
between qRT-PCR and microarray analyses. (a) The abundance of eight genes (Kpnb1, Rnf14, 
Rnd2, Ptp4a3, Eif2c2, Hipk2, Eif4ebp2, Dnmt3a, and Wsb2) in B16F0 exosomes versus B16F0 
cells were quantified by quantitative RT-PCR (mean ± s.d., N = 3). The qRT-PCR results were 
normalized to the average differential abundance of three “control” genes: Kpnb1, Rnf14, and 
Rnd2. (b) The relative abundances of mRNAs assayed by qRT-PCR were compared against the 
relative abundances of mRNAs assayed by cDNA microarray. The dotted line indicates that the 
two different assays provide the same results for relative abundance. (c) Full-length coding 
sequences (ORFs) were amplified by semi-quantitative RT-PCR. Equal concentrations of RNA 
were reverse-transcribed into cDNA and amplified by PCR. After 25 cycles, full-length open- 
reading frame amplicons were monitored every three cycles and resolved on agarose gel 
before the amplification was saturated. 
 
 
 
B16F0 exosomes for subsequent pathway enrichment analysis (Figure 3d, P <1e-9 
vs. the negative control probesets). 
 
To validate the cDNA microarray results, we amplified a subset of the mRNA 
using quantitative RT-PCR (Figure 4a and b). As endogenous loading controls for 
exosomes are unclear, we selected three genes to serve as loading controls, Rnf14, 
Rnd2 and Kpnb1, that had equal abundance between the cell and exosome samples 
based on the microarray results. In addition, we selected an additional subset of 
genes that appeared to be more abundance in exosomes: Ptp4a3, Hipk2, Eif2c2, 
Wsb2, Eif4ebp2 and Dnmt3a. Overall, the qRT-PCR results were consistent with 
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the cDNA microarray results in assaying the relative abundance between cells and 
exosomes for the different genes as the correlation coefficient was determined to 
be 0.922 (Figure 4b). Dnmt3a was the most abundant of the mRNAs assayed by 
PCR. We also used semi-quantitative PCR to confirm that the exosomal mRNAs 
were intact rather than fragmented (Figure 4c). We amplified 7 ORFs, Ptpn11, 
Eif4ebp2, Wsb2, Ptp4a3, Kpnb1, Rnd2 and Actb, out of the total RNAs purified 
from both B16F0 cells and exosomes (Figure 4c). Similar to the qRT-PCR results, 
ORFs of the 3 loading control genes, Kpnb1, Rnd2 and Actb,  seemed  to  have 
similar abundance between the two samples and mRNA for the genes, Ptpn11, 
Eif4ebp2, Wsb2 and Ptp4a3 displayed enriched abundance in the B16F0 exosome 
samples. Collectively, the gene expression results suggest that mRNAs are 
selectively packaged into exosomes and that the mRNAs are intact ORFs. 
 
3.3.4. B16F0 exosomes can deliver biological payload to T lymphocytes. 
 
 
 
As a subset of mRNAs were selectively enriched in exosomes, we used a 
pathway enrichment algorithm to identify biological pathways that are associated 
with mRNAs that are enriched in exosomes. As indicated in Figure 3d, the Enrichr 
pathway enrichment algorithm 33 was used to annotate 145 enriched mRNAs in 
B16F0 exosomes and identified 18 signaling pathways that had positive combined 
scores (see Table 1). Interestingly, several of the pathways are closely associated 
to the anti-tumor immunity, with the Type I Interferon signaling pathway having 
the lowest p-value and the IL-2, the T cell receptor, and Type II Interferon 
signaling pathways all having a positive combined score. One of the challenges 
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Type I interferon signaling 0.013 -1.565 0.680 PTPN11; RAPGEF1 
 
 
IL-5 signaling pathway 
 
0.104 
 
-1.292 
 
0.174 
 
RAPGEF1; PTPN11; MAPK14 
 
B cell receptor signaling pathway 0.151 -1.393 6.12E-02 RAPGEF1; PTPN11; CREB1; MAPK14 
 
Wnt signaling pathway 0.262 -0.772 3.39E-02 CTBP1; CCND1; HIPK2; CSNK1D 
 
Insulin signaling 0.396 -0.376 1.65E-02 RAPGEF1; PTPN11; MAPK14 
 
p38 MAPK signaling pathway 0.253 -0.204 8.95E-03 CREB1; MAPK14 
 
TGFβ signaling pathway 0.355 -6.27E-02 2.76E-03 SMAD5 
 
 
0.033 
 
-1.685 
 
0.732 
 
RAPGEF1; PTPN11 
0.022 -1.652 0.718 GNPAT; PPAP2C 
 
0.050 
 
-1.698 
 
0.532 
 
RAPGEF1; CREB1; PTPN11; MAPK14 
 
receptor 
Triacylglyceride synthesis 
 
 
IL-3 signaling pathway 
Id (Inhibitor of DNA 
signaling pathway 
binding) 
IL-4 signaling pathway  
 
 
 
Table 1 Pathways that influenced by the enriched mRNAs from B16F0 exosomes. 
 
Pathways *P-value  
*Z- 
score 
 
*Combined 
Score 
 
 
Enriched Genes 
Signaling of hepatocyte growth factor 
 
 
 
 
 
 
  
0.069 
 
-1.537 
 
0.325 
 
ELK4; SMAD5 
0.090 -1.406 0.189 HMGA1; PTPN11; MAPK14 
 
IL-2 signaling pathway 
 
0.124 
 
-1.550 
 
0.135 
 
CREB1; PTPN11; MAPK14 
 
EGFR1 signaling pathway 
 
0.189 
 
-1.301 
 
5.72E-02 
 
RALB;ELK4; PTPN11; CREB1; MAPK14 
 
T cell receptor signaling pathway 
 
0.296 
 
-0.619 
 
2.72E-02 
 
RAPGEF1; PTPN11; CREB1 
Myometrial relaxation and contraction 
pathways 
 
0.380 
 
-0.372 
 
1.64E-02 
 
ADCY7; GRK6; CREB1 
 
IL-9 signaling pathway 
 
0.174 
 
-0.134 
 
5.89E-03 
 
PTPN11 
 
Type II interferon signaling (IFNG) 
 
0.260 
 
-6.63E-03 
 
2.91E-04 
 
PTPN11 
*: P-value is computed from the Fisher exact test.  The Z-score is a statistical ranking metric derived from 
running the Fisher exact test for many random gene sets in order to compute a mean rank and standard deviation 
from the expected rank for each term in the gene-set library and finally calculating a z-score to assess the 
deviation from the expected rank. Combined score is calculated from p-value and z-score. 
 
 
with pathway enrichment results is that genes associated with a specific pathway 
can either promote or inhibit signal transduction. The gene that was common to 12 
out of the 18 signaling pathways  was Ptpn11. Ptpn11 encodes protein tyrosine 
phosphatase, non-receptor type 11, which is also known as SHP2, and negatively 
regulates a variety of signaling pathways through two tandem Src homology-2 
domains. 
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Figure 5. PTPN11 was dose-dependently increased in T lymphocytes when treated with 
exosomes from B16F0 but not Cloudman S91 or Melan-A cell lines. (a) Representative flow 
cytometry results for 2D6 T cells stained using a PE-conjugated PTPN11 mAb following 
incubation with 200 µg-protein/ml B16F0 exosomes (NanoDrop Assayed) for 30 minutes (black 
curve). Background level of PTPN11 was assayed in untreated 2D6 cells (red curve). Isotype 
stained (blue curve) and unstained 2D6 cells (gray shaded) were used as negative controls. (b) 
The median MFI associated with PTPN11 staining in 2D6 cells following incubation with different 
sources of exosomes at different concentrations (0.1, 1, 10, 100 and 200 µg-protein/ml denoted 
on x-axis). The 2D6 cells were incubated with the indicated concentrations of B16F0 exosomes 
(blue circles), Cloudman S91 exosomes (red squares), and Melan-A exosomes (black crosses). 
Statistical differences were assessed using Student’s t-test, * P < 0.05 for B16F0 exosome- 
incubated cells versus Cloudman S91 exosome-incubated cells, ** P < 0.01 for B16F0 exosome- 
incubated cells versus Melan-A exosome-incubated cells 
 
 
 
Given the potential role for PTPN11in negatively regulating these Interferon, 
IL-2, and T cell receptor signaling pathways, we focused next on whether 
exosomes can deliver a biological payload to upregulate PTPN11 in T 
lymphocytes. To answer this question, we incubated 2D6 T cells with freshly 
purified exosomes derived from either B16F0, Cloudman S91, and Melan-A cells 
and monitored the abundance of PTPN11 in the 2D6 T cells by flow cytometry 
(Figure 5). Under basal conditions, 2D6 T cells had a median MFI associated 
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with PTPN11 staining equal to 450. Exposing 2D6 T cells to 200 µg/ml of B16F0 
exosomes doubled the PTPN11 levels in 2D6 T cells. This increase in PTPN11 
levels was dose-dependent and unique to the B16F0 exosomes, as shown in Figure 
5b. In contrast, PTPN11 levels in 2D6 T cells stimulated with either Cloudman 
S91 exosomes or Melan-A exosomes were not significantly different for increasing 
concentrations of exosomes. As these results suggested that exosomes from B16F0 
but not Cloudman S91 or Melan-A cells can deliver a biological payload to 
increase PTPN11, we next tested whether an increase in the corresponding proteins 
for mRNAs that are highly enriched in B16F0 exosomes can, in isolation, impact T 
cell function. In particular, we focused on two proteins, PTPN11 and DNMT3A, 
that had enriched mRNA in B16F0 exosomes. 
 
3.3.5. Increased PTPN11 inhibited T cell proliferation in response to IL-2. 
 
 
 
Given the association of local proliferation of CD8+ T cell with tumor 
regression and the role of PTPN11 in negatively regulating both IL-2 and T cell 
receptor signaling pathways, we hypothesized that an increase in PTPN11 levels 
could inhibit T cell proliferation. As a model for CD8+ cytotoxic T lymphocytes 
that proliferates in response to IL-2 stimulation, we used the CTLL-2 cell line to 
test whether T cell proliferation was inhibited by an increase in PTPN11 in 
response to gene transfection using two different Ptpn11 expression plasmids that 
each encoded a different Ptpn11 isoform. The two isoforms differed in that 
isoform 2 uses an alternative in-frame splice site in the 3’ coding  region  and 
encodes a slightly shorter protein. As the two expression plasmids containing the 
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Figure 6. An increase in PTPN11 inhibited the proliferation of CTLL-2 cells in response to IL-2. (a) 
At the indicated time points, PTPN11 was assayed in CTLL-2 cells following a 40 hour recovery in 
complete medium after transient transfection with expression plasmids containing either the 
gene for GFP (blue circles and solid line) or Ptpn11 (red triangles and dotted line). (b, c) CTLL-2 T 
cells were transfected with Ptpn11 plasmids (red), GFP plasmids (blue), or no plasmid control 
(green), recovered for 40 hours in complete medium, stained using CellTrace Violet (CTV), and 
then stimulated with 2000 U/ml IL-2. Following 48 hours of stimulation with IL-2, the levels of 
PTPN11 and dilution of CellTrace Violet in live cells were assayed by flow cytometry, where at 
least 20,000 events were acquired. The results are representative of at least three replicates. (b) 
Scatter plots summarized the intensity of PTPN11 staining versus CellTrace Violet staining for 
cells transfected with a GFP plasmid. Similar results for untransfected CTLL-2 cells and cells 
transfected with a PTPN11 plasmid are shown as a single contour that encloses 95% of the 
population (green oval: untransfected CTLL-2 cells, red oval: PTPN11-tranfected CTLL-2 cells). (c) 
Histograms of CellTrace Violet staining in three biological replicates of untransfected (green 
curves), GFP-transfected (blue curves), and PTPN11-transfected (red curves) observed after 48 
hours were compared to CTLL-2 cells fixed at 0 hours (gray shaded curve). 
 
 
two different Ptpn11 isoforms behaved similarly in our hands, the results using the 
plasmid containing Ptpn11 isoform 1 are shown (Figure 6). Following post- 
transfection conditioning, PTPN11 transiently increased in CTLL-2 cells 
transfected with the Ptpn11 plasmid, in comparison with CTLL-2 cells transfected 
by a plasmid encoding GFP. Based on these results, we used the 48 hour time 
point to assay PTPN11 levels and differences in cell proliferation. Using CTLL-2 
cells transfected with the plasmids encoding either Ptpn11 or gfp or without a 
plasmid, we stained the cells using CellTracer Violet (CTV) and stimulated the 
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cells with 2000 U/ml of IL2. After 48 hours, we assayed CTV staining  and 
PTPN11 levels in live CTLL-2 cells associated with the different treatment groups 
by flow cytometry (Figure 6b and c). In looking at the distribution in PTPN11 
abundance versus CTV staining, we saw an inverse correlation between an 
increase in PTPN11 abundance and a decrease in cell proliferation, as measured by 
an increase in CTV staining (Figure 6b). The decrease in cell proliferation in cells 
transfected with the plasmid encoding Ptpn11 was consistently observed across the 
biological replicates (Figure 6c). These results suggested that, in isolation, an 
increase in PTPN11 abundance functionally inhibited CTLL-2 proliferation in 
response to IL-2 stimulation. 
 
3.3.6. Increased DNMT3A inhibited T cell production of IFN-γ 
 
 
 
DNA Methyltransferase (DNMT) 3A reportedly represses Th1 gene 
expression, including IFN-γ production, through DNA methylation 34,35. As we 
had found that Dnmt3a was highly enriched in B16F0 exosomes relative to the 
parental cells (Figure 3f), we hypothesized that delivery  of  Dnmt3a  to  T  cells 
could inhibit IFN-γ production. To test this, we used 2D6 T  cells  as  a  model 
system and assayed intracellular accumulation of IFN-γ in response to calcium 
ionophore and TPA stimulation as a functional response. We first transfected 2D6 
T cells with different plasmids encoding one of two DDK-tagged isoforms of 
Dnmt3a, or gfp. The second isoform of Dnmt3a initiates translation at a 
downstream in-frame start codon that results in a shorter N-terminus compared to 
isoform 1. Following transfection, DNMT3A expressed by both isoforms increased 
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Figure 7. Dnmt3a protein upregulation inhibited IFN-γ production. (a) DDK-tagged Dnmt3a 
expression was assessed by flow cytometry in 2D6 cells at 24 and 48 hours following   
transfection with Dnmt3a cDNA-containing plasmids. (b) Following treatment with calcium 
ionophore and TPA in conjunction with GolgiStop, intracellular levels of IFN-γ were assayed by 
flow cytometry in live 2D6 cells transfected using the following cDNA plasmids: Dnmt3a variant 1 
(blue), Dnmt3a variant 2 (black), or GFP (red). GFP-transfected 2D6 cells were used as a positive 
control. The negative control was 2D6 cells treated with GolgiStop but not calcium ionophore or 
TPA (gray shaded). Green dotted vertical line indicates a data-driven threshold for positive IFN-γ 
expression, where 95% of the negative control cells have lower IFN-γ MFIs. The results are 
representative of at least two independent experiments. Using at least 6,000 live cell events, 
statistical significance of the distributions in PE MFI (IFN-γ) was assessed with a probability 
binning approach whereby the univariate distribution was discretized into 100 bins and the 
number of events in the positive control and sample bins were compared with a Pearson’s 
χ2 test (*P-value < 1e-10). 
 
 
in cellular abundance over time such that most cells were positive by 48 hours 
(Figure 7a). Using 48 hours as a pre-conditioning period following transfection, we 
then stimulated 2D6 cells from the different experimental groups for IFN-γ 
production and analyzed intracellular IFN-γ expressions by flow cytometry (Figure 
7b). Unstimulated 2D6 cells were used as a negative control. While the differences 
between groups were subtle, fewer 2D6 cells transfected with expression plasmids 
for either isoform of Dnmt3a were positive for intracellular IFN-γ staining (36- 
38%) compared with GFP-expressing 2D6 cells (44%) and the distributions were 
82  
 
significantly different (Pearson’s χ2 test, p < 1e-10). In summary, an increase in 
DNMT3A, in isolation, inhibited IFN-γ production in 2D6 T cells. 
 
3.3.7. B16F0 exosomes inhibited multiple aspects of an antigenic response in primary 
CD8+ T cells. 
 
Collectively, the transfection studies suggest that Ptpn11 and Dnmt3a,  two 
genes that had mRNA enriched in B16F0 exosomes relative to parental cells, can 
individually inhibit aspects of T cell function. Yet, other aspects of  this  study 
suggest that exosomes contain a more complicated composition of mRNAs (see 
Figures 3 and 4) and that this composition may vary between cell lines (see Figure 
5). To directly assess whether exosomes influence T cell function, we 
characterized the impact of B16F0, Cloudman S91, and Melan-A exosomes on 
primary CD8+ T cells. First, we isolated transgenic CD8+ T cells from mouse 
splenocytes, of which 94.6% were positive for CD3+ CD8+ and 71.8% were 
considered to be naïve CD8+ T cells (CD3+ CD8+ CD62L+ CD44-). After 
isolation, the primary CD8+ T cells were all stained by CellTrace Violet, cultured 
in media containing IL-12 and anti-IL-4 mAb to promote a Tc1 phenotype, and 
activated with anti-CD3/CD28 beads, where blank beads where used as a negative 
control. In addition, CD8+ T cells activated with anti-CD3/CD28 beads were also 
stimulated with different concentrations of exosomes freshly isolated from B16F0, 
Cloudman S91, and Melan-A cells. After 24 hours, cell viability, cell proliferation, 
and IL12RB2 expression were assayed under the different experimental conditions 
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d and stained by CellTrace Violet at 0hr, stimulated for 
24 hrs with anti-CD3/CD28 beads and exosomes derived from B16F0, Cloudman S91, and Melan-A 
cells. (a) Flow cytometric events were gated into cells (blue polygon) and dead/dying cells were 
excluded based on Live/Dead staining (yellow). (b) The percentage of viable cell events were 
compared between CD8+ T cells stimulated for 24 hrs with anti-CD3/CD28- conjugated beads 
(CD3/CD28 beads) and different concentrations of exosomes derived from B16F0, Cloudman S91,  
and Melan-A cells. (c) Cell proliferation was assessed using a shift in CellTracer Violet, as assayed by 
flow cytometry. Cells at 0 hours were used as a reference condition (gray shaded) and cells 
stimulated for 24 hours with CD3/CD28 beads were a positive control (black curve). Colored lines 
indicate intensity thresholds associated with progressive cell proliferation. (d) The relative T cell 
proliferation for the indicated experimental conditions are summarized, where individual data points 
are shown and lines indicate the average response. (e) IL12RB2 was assayed in CD8+ T cells by flow 
cytometry, where representative histograms for the indicated experimental conditions are shown. (f) 
The median IL12RB2 staining results were compared between CD8+ T cells stimulated with  
CD3/CD28 beads and different concentrations of exosomes derived from B16F0, Cloudman S91, and 
Melan-A cells. Results were obtained in biological triplicate. A significant difference between 
exosome-treated and the positive control was assessed using a two-sided Student’s t-test assuming 
unequal variance (* P < 0.01). One replicate at the 200μg/ml B16F0 exosome condition was 
considered an outlier, as indicated by the arrow in panels b, d, and f. 
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by flow cytometry (Figure 8). Viability was > 85% in T cells activated with either 
blank or anti-CD3/CD28 beads (Figure 8b). In contrast, B16F0 exosomes dose- 
dependently decreased cell viability with an EC50 equal to 136 g/ml while the 
Cloudman S91 exosomes had an EC50 equal to 200 g/ml. Melan-A exosomes 
had a minimal effect on cell viability, where viability was decreased to 65% only 
at the highest concentration (500 g/ml). In live CD8+ T cells, CellTrace Violet 
was used to quantify the extent of T cell proliferation under the different 
experimental conditions (Figure 8c). In primary CD8+ T cells activated with blank 
beads, 90% of the population was comprised of generation 0 (G0) cells after 24 
hours (Figure 8d). Activation using anti-CD3/CD28 beads promoted cell 
proliferation, where 67% of the population was comprised of G0 cells and 32% of 
the population had proliferated once (G1). Interestingly, the exosomes had 
different effects on these primary CD8+ T cells, where B16F0 exosomes inhibited 
cell proliferation (81.2% G0/16.4% G1 for 200 g/ml) and Cloudman S91 
promoted cell proliferation (46.5% G0/48.7% G1/4.4% G2). Again, the Melan-A 
exosomes seemed to have minimal effect with a subtle promotion of cell 
proliferation seen at the 500 g/ml dose (58.2% G0/ 35.1% G1/3.3% G2). The 
addition of IL-12 and anti-IL-4 mAb promoted the upregulation of IL12RB2 over 
the 24 hour culture conditions (Figure 8e). This increase in IL12RB2 receptor 
expression was dose-dependently inhibited by B16F0 exosomes with  an  EC50 
equal to 171 g/ml, while the Cloudman S91 and Melan-A exosomes had no effect 
on  IL12RB2  expression  (Figure  8f).  Overall,  the  primary  CD8+  T  cell  studies 
suggest that B16F0 exosomes impact T cell function by inhibiting cell viability, 
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decreasing cell proliferation, and by inhibiting the polarization of CD8+ T cells 
towards a type 1 phenotype. In contrast, exosomes derived from the other two 
melanocyte cell lines have very different effects. Cloudman S91 exosomes inhibit 
cell viability but promote cell proliferation and have no effect on Tc1 polarization, 
while exosomes from Melan-A cells seem to have little functional impact on 
primary CD8+ T cells. 
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3.4. Discussion 
 
 
 
Supported by  the emerging  clinical data using  immunotherapies for cancer, 
identifying local mechanisms of immunosuppression within the tumor 
microenvironment is a key barrier for broadening the clinical benefit of 
immunotherapies for cancer36. As exosomes represent an emerging mode of cell- 
to-cell communication through the delivery of proteins and coding and non-coding 
RNAs, the objective of this study was to characterize the impact  of  exosomes 
derived from three melanocyte cell lines on T cell function, with an emphasis on 
exosomal mRNA. The three melanocyte cell lines include the B16F0, a non- 
immunogenic transplantable model for malignant melanoma; the Cloudman S91, 
an immunogenic transplantable model for malignant melanoma; and Melan-A, a 
model of normal melanocytes 37,38. In short, we found that all  three  cell  lines 
secrete exosomes of a similar size and morphology but exosomes derived from 
each cell line elicit a different response in T cells. Exosomes derived from B16F0 
cells contain proteins present in the parental cell and intact mRNAs that are 
differentially packaged into exosomes. Exosomal mRNAs that are enriched in 
B16F0 exosomes target a number of pathways that are important for anti-tumor 
immunity, including T cell proliferation6, IFN- production39, and responsiveness 
to IL1240,41. In contrast, exosomes derived from Cloudman S91 increased T cell 
proliferation over anti-CD3/CD28 antigen presentation beads alone while Melan-A 
exosomes seemed to have little effect on primary CD8+ T cells. 
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Therapeutic modulation of immune checkpoints is one of the most recent 
clinical advances in the treatment of melanoma4,5,42. Conceptually, immune 
checkpoints limit the clonal expansion and effector activity of T cells by engaging 
signaling proteins that inhibit T cell signal transduction. Antibodies against these 
immune checkpoints, such as anti-CTLA4 mAbs, enable increased  clonal 
expansion and enhanced immune cell infiltration into and proliferation within the 
tumor microenvironment6. Pre-clinical studies using the B16 model indicate that 
the efficacy of immune checkpoint modulation depends inversely on tumor load 11. 
In comparing exosomes from these three melanoma models, we found that only 
B16F0 exosomes were able to increase PTPN11 dose-dependently, which 
suppressed T cell proliferation. While the exact role that PTPN11 plays in signal 
transduction remains controversial, reviewed in43,44, PTPN11 is a phosphatase that 
can be engaged by both the PD-1/PD-L1 and CTLA-4 signaling  pathways  to 
inhibit T cell signaling45–47. We also observed that fresh exosomes derived from all 
three cell lines were uniformly distributed in size with average diameters between 
160 and 166 nm. This is important as the size of exosomes can establish 
concentration gradients within tissues, where the local concentration is increased 
by the rate of cellular production within a tissue and decreased by convective and 
diffusive transport mechanisms. While exosomes are released by  essentially  all 
cells, malignant cells derived from melanoma release exosomes at a greater rate 
compared to normal controls 48, which may be attributed to a p53-mediated stress 
response17. The convective and diffusive transport mechanisms  depend  on 
molecular size, such that macromolecules (3-5 nm in diameter) and nanoparticles 
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that are less than 50 nm are easily transported to the draining lymphatics from the 
interstitial tissue by convective flow while the extracellular matrix sterically 
hinders the movement of larger particles49,50. Specifically, nanoparticles with a 
diameter of 200 nm have 10-20 times worse tissue penetration than nanoparticles 
of 50 nm in size51. While our observed exosome sizes may seem at odds with the 
conventional wisdom that exosomes are 30-100 nm in diameters 52,53, prior 
measurements of exosome sizes may be biased by storage conditions prior to 
imaging that result in exosome shrinkage and fragmentation 25,54. Collectively, the 
results suggest that tumor-derived exosomes can locally accumulate with time 
within the tumor microenvironment to deliver a complex payload that dose- 
dependently suppresses immune cell function. As observed previously in the B16 
model11, the time dependence of this immunosuppressive effect can explain a 
common criticism of pre-clinical mouse models where immunotherapies are tested 
before the local immunosuppressive network has established55. 
 
Organizing an effective anti-tumor immune response among a variety of cell 
types involves a complicated network of intercellular  communication.  An 
emerging idea that follows from thinking of cancer as an evolutionary process is 
that malignant cells develop mechanisms to alter this local intercellular network of 
communication56. Given the importance of Interleukin-12 in locally promoting anti-
tumor immunity, exosomes derived from B16F0 suppress  cell  response  to IL12 in 
two ways. The first is an indirect mechanism where B16F0 cells create a cytokine 
sink for Interleukin-12 by over-expressing one component of the IL-12 
receptor, IL12RB229. Here, we find that exosomes secreted by B16F0 cells also 
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contain IL12RB2, which can enhance the cytokine sink effect. The second is a 
direct mechanism where the delivery of B16F0 exosomes to primary CD8+ T cells 
dose-dependently inhibited IL12RB2 expression. These mechanisms for inhibiting 
immune cell response to IL12 complement previous observations that tumor- 
derived Wnt-inducible signaling protein 1 (WISP1) suppresses immune cell 
response to IL1229,57. In contrast to secreted proteins that have a defined biological 
function, we also observed that all of the cell lines  secreted  exosomes  with  a 
similar morphology but elicited different biological effects through delivery of 
unique biological payloads. Supported by the non-random loading of intact open 
reading frames into B16F0 exosomes that targeted a number of immune-related 
pathways, the exosomal payload appears to be a remnant of selective pressure 
associated with somatic evolution. We note that the mouse species from which 
these cell lines were derived have different propensities for oncogenesis. 
Specifically, DBA/2 mice are sensitive and C57Bl/6 mice are resistant to skin 
oncogenesis using carcinogens (DMBA plus TPA)58, which were used to isolate 
the B16 and Cloudman S91 cell lines from spontaneous tumors, respectively 59,60. 
It follows then that inbred mouse strains that are resistant to oncogenesis have 
strong selective pressure to maintain normal tissue homeostasis. Collectively, 
malignant cells that arise in resistant mouse strains, as exemplified by the B16 
model, must develop multiple mechanisms to escape from this selective pressure. 
Secretion of WISP1, creation of a cytokine sink for IL12, and exosomal delivery of 
a complex biological payload to suppress T cell proliferation, viability, and 
IL12RB2  expression  are  some  of  the  additional  mechanisms  that  we  have 
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identified in the B16 model. While in vivo studies will be necessary to establish 
the sensitivity of these mechanisms to therapeutic modulation, identifying how the 
local networks for intercellular communication are changed during oncogenesis is 
the first step in developing therapeutic strategies to restore the intercellular 
signaling networks associated with normal tissue homeostasis and to enhance the 
response rate for existing cancer immunotherapy, such as immune checkpoint 
modulators. 
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C H A P T E R  4 :  P A T H  F O R W A R D 
 
 
 
 
As advances in cancer immunotherapy tries to improve patients' survival, 
understanding how exosomes influence intercellular communication has piqued a 
great amount of research interests. In this dissertation, our work  suggests  that 
cancer exosomes have the potential to suppress anti-tumor immunity in multiple 
ways. In particular, we identified multiple functional molecules including RNAs 
and transmembrane receptor components are enriched on melanoma exosomes. 
These functional molecules correspond to distinct mechanisms of regulating 
cellular signal transduction and modulate cytokine activity. Our findings provide 
insight into the potential of cancer exosomes in repressing immunity, which 
highlights the need for further investigation into the intersection of exosome 
biology and cancer immunology. Motivated by our present work, future directions 
may focus on the following three topics. First, overexpression of IL12RB2 within 
the melanoma microenvironment may be shaped by cross-talk between 
inflammatory IL12 and/or immunosuppressive IL35  signaling.  Therefore, 
identifying how IL12RB2 overexpression influences these signaling pathways is 
an interesting topic that will improve our understanding of the role of melanoma 
exosomes in cancer immunotherapy. Since exosomes contain a complex mixture 
of mRNA and miRNAs, the second topic involves identifying the collective effect 
of those coding and non-coding RNAs on gene expression of a recipient cell. This 
may shed light on potential mechanisms to block tumor immunosuppression 
mediated by exosomes. In our study, the upregulation of PTPN11 or DNMT3A in 
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T cells inhibit their functions. The third topic is to investigate whether the 
inhibitors of the PTPN11 or DNMT3A proteins, such as cryptotanshinone1 
(inhibiting PTPN11), and decitabine2 (inhibiting  DNMT),  have  adjuvant  effects 
that can stabilize the anti-tumor effects of lymphocytes in vivo, in a purpose of 
extending the durable immune response for cancer treatment. Such studies may 
identify novel medicines for cancer immunotherapy and increase overall survival. 
In the following paragraphs, we will discuss these future research topics in more 
detail. 
 
The first future research direction is to investigate the impact of IL12RB2 
overexpression within the melanoma microenvironment. IL12RB2 is binding and signaling 
component of the receptors for two cytokines: IL12 and IL35, both belonging to IL12 
family. Yet, those two cytokines act in opposing ways for regulating the host immunity. 
IL12 is proinflammatory in that it boosts the natural killer cells and cytotoxic T lymphocyte 
(CTL) activity, causes polarization of T helper cells towards Th1 phenotype3,4. By contrast, 
IL-35 is produced by Treg and is suppressive, in that IL35 functions in repressing the 
proliferation of conventional T cells, stimulating conversion of naive T cells into Treg cell 
population that can produce IL35 and expand such immunosuppression5–8. The IL12 
cytokine family includes IL12, IL35, IL23 and IL27. Chain sharing of cytokines as well as 
among the receptors is a unique feature of the IL12 family9,10. Pertaining to IL12RB2, a 
functional IL12 receptor is a transmembrane protein comprised by heterodimer IL12RB1- 
IL12RB211–13, whereas IL35 has been found being capable of binding and signaling 
through either heterodimer IL12RB2-gp130, or homodimers IL12RB2-IL12RB2 and 
gp130-gp1309,10,14,15.  For  IL12  binding  and  signaling,  IL12RB2  predominates  this 
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processes over IL12RB1 because previous study has revealed that the IL12RB2-deficient 
mice are defective in IL12-mediated signaling despite the presence of high affinity IL12 
binding sites on IL12RB116. Such critical role of IL12RB2 to IL12 might extend to IL35 
binding and signaling, due to the ubiquitous expression of gp13017. In the previous 
chapters, our discussion about the IL12RB2 expression on melanoma exosomes focuses on 
IL12 signaling, due to the prominent populations of therapeutically-induced Th1 cells in 
cancer immunotherapy, for instance, "preparative lymphodepletion" is currently 
recommended and widely performed for temporary ablation of autologous lymphocytes 
(including Treg that produces IL35) in patients for a purpose of improving the efficacy of 
adoptive cell transfer that follows. For future investigation, it is interesting to interrogate 
whether and how the two cytokines, IL12 and IL35, compete for IL12RB2, as well as how 
their distinct functional profiles interact, in the context of immune cells and also in the 
cancer cells, i.e. melanoma cells. It is worth to identify the expression of gp130 and 
IL12RB1 on those B16F0 exosomes, also, to investigate the potential dimeric structures of 
those receptor components of IL12RB2, IL12RB1 and gp130. Moreover, the binding of 
cytokines IL12, IL35, and the fate of such cytokine bond with the extracellular vesicles, are 
fundamental inquiries that will improve our understanding of the roles that cancer 
exosomes play. For instance, will cancer exosomes bind cytokines and forward them to 
modulate either immune or cancer cells? Will such exosome-mediated cytokine 
binding/delivery take part in the tumor growth and metastasis? Does "cytokine sink" of 
IL12 exist at the tumor microenvironment due to the overexpression of receptor 
components on melanoma exosomes? Those are all interesting directions. 
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Other than IL12RB functions, the interaction of those coding and non-coding RNAs 
enclosed in melanoma exosomes is an interesting research topic that may shed light on 
developing counteracting strategies to deactivate the gene regulations and tumor resistance 
mediated by cancer exosomes. Exosomes contain miRNAs and mRNAs, however, the roles 
of mRNAs from those extracellular vesicles are much less reported in comparison with the 
miRNAs, partly due to some previous arguments have thought only miRNAs and degraded 
mRNAs in small pieces can be contained by exosomes. In this work, we demonstrate the 
intactness of mRNAs from exosomes. We also investigate the functions of those mRNAs 
being delivered by cancer exosomes and the inhibitory effect of Ptpn11 and Dnmt3a genes 
influencing Th1 immune response. Recent studies have suggested that the cellular 
internalization of exosomes can actively occur in recipient cells via several engulf 
pathways, i.e. endocytosis18 and phagocytosis19. This inspires our belief that the melanoma 
exosomes and the coding and non-coding esRNAs are potentially able to be uptaken by 
multiple types of cells present at the tumor sites, either cancer cells in heterogeneity, 
therapeutically-induced effector T cells or other immune cells surrounding a tumor. 
Obviously, the mechanisms of how exosomal mRNA and miRNA affect in recipient cells 
are distinct, in that the mRNA induces expression whereas miRNA function through 
inhibiting gene transcription and/or expression. Therefore, the interactions of those coding 
and non-coding RNAs are one direction need to be studied and this may provide new 
perspectives to the current immunosuppressive mechanisms that facilitate tumor resistance. 
To achieve those goals, computing and modeling methods are useful tools in terms of 
exploring the network constructed by multiple active elements in those coding and non- 
coding RNAs. Experimental methods are also required especially to confirm results out of 
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calculations. This study will provide a system perspective to the roles of cancer exosomes 
conveying multiplex functional RNAs that are capable of shaping a complicated, and 
potentially reactive microenvironment at the tumor site. Particularly relevant to our study in 
this work, the PTPN11 and DNMT3A signaling in T cells are two pathways worth to be 
studied in terms of understanding the dynamics of their upregulations, confirming their 
prominent effects, potentially conjugating complex, and trying to explore counteracting 
strategies that may deactivate such gene regulations. RNA interference tests and chemical 
reagents that are inhibitors of PTPN11 and DNMT, cryptotanshinone (inhibiting PTPN11), 
and hypomethylating agents (inhibiting DNMT), i.e. decitabine, can be useful tools, 
especially for in vitro studies. This will enhance our understanding of the two pathways, in 
addition the results will be the basis of our next topic for future directions, to explore the 
anti-tumor effects of those inhibitory agents antagonizing specific mRNA derived from 
melanoma exosomes. 
 
Based on our understanding of the immunosuppressive mechanism mediated by cancer 
exosomes and their exosomal mRNAs, antagonists of PTPN11 and/or DNMT are 
potentially immunomodulatory agents that may stop the negative effect from melanoma 
exosomes, stabilize anti-tumor immune response at the tumor milieu and extend the durable 
benefits in cancer immunotherapy. Elevated levels of DNA methylation with aberrant 
promoter regions hypermethylation of tumor suppressor genes are characteristics of many 
cancer types. High frequency of DNMT3A mutations have been discovered in human 
cancers20,21 and have association with poor prognosis22,23. Hypomethylating agents (HMAs) 
that can downregulate DNMTS, azacitidine and decitabine, have proved tumor regression 
effects and the mechanisms were thought as HMAs can induce silenced tumor suppressor 
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genes24–26 and/or cytotoxicity due to DNA-hypermetholation in cancers 27–30. FDA have 
approved those drugs for the treatment of myelodysplastic syndrome due to improved 
survival in clinics as well as the durable effects31. Other than those two mechanisms for 
cancer treatment, mounting evidences have recently suggested the immunomodulatory role 
of low-dose decitabine that can induce or alter autologous anti-tumor immune response that 
target cancer testis antigens (CTAs) expressed via MHC class I 2,32–35, i.e. MAGE 
(melanoma associated antigen genes) and NY-ESO-1 in melanoma, ovarian and other 
cancers. Such expression of CTAs were thought as induced and maintained by HMAs 
administration, however, the drug-effect dynamics  cannot be fully explained in clinics 2,32– 
35.  Our  study on  melanoma  exosomes  provides  basis  for  the  effectiveness  of  HMAs 
 
assisting the immunotherapies in the light of preventing cancer-exosomes-mediated 
immunosuppression, i.e. IFN-γ production and signaling. We suspect that IFN-γ and 
cytotoxic T lymphocytes are not the only active pathway hindered by the cancer-exosomes- 
induced DNMT3A. In fact, the actual networking of DNMTs in the development and 
differentiation of effector T lymphocytes, as well as to other immune cells pivotal on the 
cancer-immunity cycle, are still far from fully unresolved. Currently, as the adoptive cell 
transfer (ACT) based cancer management, i.e. CART, is coming into broader application in 
clinics, failure to induce durable response and occurrence of tumor resistance motivate the 
active investigation on various enhancing methods for immunotherapy. We propose the 
effect of HMAs as potentially adjuvant agents in the context of CART therapy is one 
interesting direction for the future work, targeting the DNMTs upregulation from the 
cancer-induced exosomes. Particularly, in vivo melanoma tumor model and activities of 
TILs in CART therapy are worth to be analyzed in the light of HMAs efficacy. In addition 
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to the HMAs, the inhibitory agent for PTPN11, cryptotanshinone, might be another novel 
drug potentially useful in cancer therapy. PTPN11 is ubiquitously expressed and widely 
functions in a variety of signaling pathway, including Ras-Erk, PI3K-Akt, Jak-Stat and 
NF-κB 36–38. PTPN11 mutations occurring in cancers, and also in Noonan syndrome, 
frequently lose the autoinhibition of the SH2 domains (Src homology-2 domains) at N- 
terminus to the protein tyrosine phosphatase (PTP), therefore, PTP activity and the 
substrate transformation in patients can be abnormally altered 39,40. Our study on PTPN11 
mRNAs in melanoma exosomes and its experiment-proved, repressive effect on effector T 
cell proliferation suggested a novel mechanism in cancerous origins and tumor 
immunology. However, due to the broad involvements of PTPN11 in cellular activities, the 
pivotal role of function are still not completely known. The potential of PTPN11 inhibitors 
as immunomodulatory agents needs proof-of-concept and investigations on in vivo animal 
tumor models. 
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